{'clarification_needed': False,
 'clarified_query': None,
 'clarity_score': 0.9,
 'current_step_idx': 5,
 'entities': {'candidate_claims_2020_2022_with_citations_and_repetition_indicators': ['No '
                                                                                      'content '
                                                                                      'on '
                                                                                      'this '
                                                                                      'page '
                                                                                      'relates '
                                                                                      'to '
                                                                                      'an '
                                                                                      'FDA '
                                                                                      'emergency '
                                                                                      'use '
                                                                                      'authorization '
                                                                                      'for '
                                                                                      'hydroxychloroquine '
                                                                                      'for '
                                                                                      'COVID-19 '
                                                                                      '(2020).',
                                                                                      'The '
                                                                                      'page '
                                                                                      'is '
                                                                                      'a '
                                                                                      'general '
                                                                                      'USA.gov '
                                                                                      'homepage '
                                                                                      'with '
                                                                                      'links '
                                                                                      'to '
                                                                                      'government '
                                                                                      'topics '
                                                                                      'and '
                                                                                      'services '
                                                                                      'but '
                                                                                      'contains '
                                                                                      'no '
                                                                                      'EUA '
                                                                                      'statement '
                                                                                      'or '
                                                                                      'related '
                                                                                      'details.'],
              'later_evidence_reports_2023_2025_with_key_findings_and_quotes': ['Eveleens '
                                                                                'Maarse '
                                                                                'BC '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'No '
                                                                                'significant '
                                                                                'correlation '
                                                                                'between '
                                                                                'HCQ '
                                                                                'and '
                                                                                'RR-, '
                                                                                'QRS-, '
                                                                                'or '
                                                                                'QTcF-intervals '
                                                                                '(P '
                                                                                '> '
                                                                                '0.05). '
                                                                                'Conclusion: '
                                                                                '"At '
                                                                                'plasma '
                                                                                'concentrations '
                                                                                'up '
                                                                                'to '
                                                                                '200 '
                                                                                'ng/mL, '
                                                                                'HCQ '
                                                                                'had '
                                                                                'no '
                                                                                'effect '
                                                                                'on '
                                                                                'ventricular '
                                                                                'repolarization '
                                                                                'including '
                                                                                'QTcF '
                                                                                'and '
                                                                                'T‑wave '
                                                                                'shape."',
                                                                                'Chorin '
                                                                                'E. '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'Severe '
                                                                                'new '
                                                                                'QTc '
                                                                                'prolongation '
                                                                                'to '
                                                                                '≥500 '
                                                                                'ms '
                                                                                'in '
                                                                                '23% '
                                                                                'of '
                                                                                'cases. '
                                                                                'Conclusion: '
                                                                                '"HCQ '
                                                                                'markedly '
                                                                                'lengthens '
                                                                                'QTc '
                                                                                'in '
                                                                                'COVID‑19 '
                                                                                'patients."',
                                                                                'Tang '
                                                                                'W. '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'QTc '
                                                                                'prolongation '
                                                                                'and '
                                                                                'cardiac '
                                                                                'arrhythmia '
                                                                                'reported; '
                                                                                'no '
                                                                                'significant '
                                                                                'difference '
                                                                                'in '
                                                                                'viral '
                                                                                'negative '
                                                                                'conversion '
                                                                                'versus '
                                                                                'standard '
                                                                                'care. '
                                                                                '(Regimen '
                                                                                'reported: '
                                                                                'HCQ '
                                                                                '1,200 '
                                                                                'mg '
                                                                                'OD '
                                                                                'for '
                                                                                '3 '
                                                                                'days '
                                                                                'then '
                                                                                '800 '
                                                                                'mg '
                                                                                'OD '
                                                                                'for '
                                                                                '2–3 '
                                                                                'weeks.)',
                                                                                'Borba '
                                                                                'MGS. '
                                                                                'et '
                                                                                'al. '
                                                                                '(CQ '
                                                                                'trial) '
                                                                                '— '
                                                                                'Result: '
                                                                                'Ventricular '
                                                                                'arrhythmia '
                                                                                'or '
                                                                                'QTc '
                                                                                '> '
                                                                                '500 '
                                                                                'ms '
                                                                                'reported '
                                                                                'at '
                                                                                '28 '
                                                                                'days; '
                                                                                'higher-dose '
                                                                                'group '
                                                                                'had '
                                                                                'increased '
                                                                                'occurrence '
                                                                                'of '
                                                                                'QTc '
                                                                                '> '
                                                                                '500 '
                                                                                'ms. '
                                                                                'Conclusion: '
                                                                                '"High‑dose '
                                                                                'CQ '
                                                                                'not '
                                                                                'recommended '
                                                                                'for '
                                                                                'critically '
                                                                                'ill '
                                                                                'patients."',
                                                                                'van '
                                                                                'den '
                                                                                'Broek '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'Mean '
                                                                                'QTc '
                                                                                'prolongation '
                                                                                '35 '
                                                                                'ms '
                                                                                '(95% '
                                                                                'CI '
                                                                                '28–43 '
                                                                                'ms). '
                                                                                'Conclusion: '
                                                                                '"Chloroquine '
                                                                                'significantly '
                                                                                'prolongs '
                                                                                'QTc '
                                                                                'interval."',
                                                                                'Bessière '
                                                                                'F. '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                '93% '
                                                                                'of '
                                                                                'patients '
                                                                                'displayed '
                                                                                'an '
                                                                                'increase '
                                                                                'in '
                                                                                'QTc. '
                                                                                'Conclusion: '
                                                                                '"QTc '
                                                                                'intervals '
                                                                                'increased '
                                                                                'in '
                                                                                '>90% '
                                                                                'of '
                                                                                'patients."',
                                                                                'Ramireddy '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'Baseline '
                                                                                'mean '
                                                                                'QTc '
                                                                                '448 '
                                                                                '± '
                                                                                '29 '
                                                                                'ms '
                                                                                'increased '
                                                                                'to '
                                                                                '459 '
                                                                                '± '
                                                                                '36 '
                                                                                'ms '
                                                                                '(P '
                                                                                '= '
                                                                                '0.005); '
                                                                                'critical '
                                                                                'QTc '
                                                                                'prolongation '
                                                                                'present '
                                                                                'in '
                                                                                '12% '
                                                                                'of '
                                                                                'patients '
                                                                                'overall.',
                                                                                'Cipriani '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'QTc '
                                                                                'interval '
                                                                                'longer '
                                                                                'after '
                                                                                'treatment '
                                                                                '(p '
                                                                                '= '
                                                                                '0.02). '
                                                                                'Conclusion: '
                                                                                '"Azithromycin '
                                                                                '+ '
                                                                                'HCQ '
                                                                                'prolong '
                                                                                'QTc, '
                                                                                'especially '
                                                                                'with '
                                                                                'high '
                                                                                'transaminase '
                                                                                'levels."',
                                                                                'Bun '
                                                                                'SS '
                                                                                'et '
                                                                                'al. '
                                                                                '— '
                                                                                'Result: '
                                                                                'Average '
                                                                                'automated '
                                                                                'QTc '
                                                                                'prolonged '
                                                                                'after '
                                                                                '48 '
                                                                                'hr. '
                                                                                'Conclusion: '
                                                                                '"Combination '
                                                                                'therapy '
                                                                                'with '
                                                                                'HCQ/AZT '
                                                                                'may '
                                                                                'be '
                                                                                'used '
                                                                                'in '
                                                                                'inpatients '
                                                                                'with '
                                                                                'lower '
                                                                                'respiratory '
                                                                                'tract '
                                                                                'infection '
                                                                                'but '
                                                                                'QTc '
                                                                                'increases '
                                                                                'observed."',
                                                                                'Aggregate '
                                                                                'finding '
                                                                                '— '
                                                                                'Reported '
                                                                                'range '
                                                                                'of '
                                                                                'significant '
                                                                                'QTc '
                                                                                'prolongation '
                                                                                'across '
                                                                                'included '
                                                                                'studies: '
                                                                                '12% '
                                                                                'to '
                                                                                '93% '
                                                                                'of '
                                                                                'patients.'],
              'original_claim_texts_and_sources_2020_2022': ['Date: March 28, '
                                                             '2020 — FDA '
                                                             'issued an '
                                                             'Emergency Use '
                                                             'Authorization '
                                                             '(EUA).',
                                                             'Products '
                                                             'covered: '
                                                             'hydroxychloroquine '
                                                             'sulfate and '
                                                             'chloroquine '
                                                             'phosphate '
                                                             'donated to the '
                                                             'Strategic '
                                                             'National '
                                                             'Stockpile (SNS).',
                                                             'Authorized use: '
                                                             'to be '
                                                             'distributed from '
                                                             'the SNS to '
                                                             'states and used '
                                                             'for certain '
                                                             'hospitalized '
                                                             'patients with '
                                                             'COVID-19 — '
                                                             'specifically for '
                                                             'adolescent and '
                                                             'adult patients '
                                                             'hospitalized '
                                                             'with COVID-19, '
                                                             'as appropriate, '
                                                             'when a clinical '
                                                             'trial is not '
                                                             'available or '
                                                             'feasible.',
                                                             'EUA '
                                                             'requirements: '
                                                             'fact sheets '
                                                             'providing '
                                                             'important '
                                                             'information '
                                                             'about using '
                                                             'chloroquine '
                                                             'phosphate and '
                                                             'hydroxychloroquine '
                                                             'sulfate in '
                                                             'treating '
                                                             'COVID-19 must be '
                                                             'made available '
                                                             'to health care '
                                                             'providers and '
                                                             'patients, '
                                                             'including the '
                                                             'known risks and '
                                                             'drug '
                                                             'interactions.',
                                                             'Distribution '
                                                             'logistics: the '
                                                             'SNS, managed by '
                                                             'the Assistant '
                                                             'Secretary for '
                                                             'Preparedness and '
                                                             'Response (ASPR), '
                                                             'will work with '
                                                             'the Federal '
                                                             'Emergency '
                                                             'Management '
                                                             'Agency (FEMA) to '
                                                             'ship donated '
                                                             'doses to states.',
                                                             'This '
                                                             'communication '
                                                             'informs licensed '
                                                             'prescribers and '
                                                             'dispensers of a '
                                                             'recent FDA '
                                                             'guidance '
                                                             'authorizing '
                                                             'emergency use of '
                                                             'chloroquine '
                                                             'phosphate and '
                                                             'hydroxychloroquine '
                                                             'sulfate.',
                                                             'The '
                                                             'authorization '
                                                             'details are '
                                                             'described in the '
                                                             'Scope of '
                                                             'Authorization '
                                                             '(Section II) of '
                                                             'the FDA letter '
                                                             'referenced by '
                                                             'the '
                                                             'communication; '
                                                             'the emergency '
                                                             'use is for the '
                                                             'treatment of '
                                                             'COVID-19.',
                                                             'LARA (Michigan '
                                                             'Department of '
                                                             'Licensing and '
                                                             'Regulatory '
                                                             'Affairs) '
                                                             'acknowledges the '
                                                             'role of '
                                                             'prescribers and '
                                                             'dispensers and '
                                                             'urges '
                                                             'responsible '
                                                             'prescribing and '
                                                             'dispensing '
                                                             'practices.',
                                                             'Signed by: Debra '
                                                             'Gagliardi, '
                                                             'Director, Bureau '
                                                             'of Professional '
                                                             'Licensing.',
                                                             'Date: 06/15/2020 '
                                                             '— FDA revokes '
                                                             'the emergency '
                                                             'use '
                                                             'authorization '
                                                             '(EUA) for '
                                                             'chloroquine '
                                                             'phosphate and '
                                                             'hydroxychloroquine '
                                                             'sulfate.'],
              'persistence_explanations_and_sources_2021_2025': ['False news '
                                                                 'spreads '
                                                                 '“significantly '
                                                                 'farther, '
                                                                 'faster, '
                                                                 'deeper, and '
                                                                 'more '
                                                                 'broadly” '
                                                                 'than true '
                                                                 'news '
                                                                 '(Vosoughi et '
                                                                 'al., 2018): '
                                                                 'analysis of '
                                                                 '~126,000 '
                                                                 'Twitter '
                                                                 'cascades '
                                                                 'found the '
                                                                 'disparity '
                                                                 'was driven '
                                                                 'by human '
                                                                 'behavior '
                                                                 'rather than '
                                                                 'bots. False '
                                                                 'stories '
                                                                 'tended to be '
                                                                 'more novel '
                                                                 'and '
                                                                 'emotionally '
                                                                 'evocative '
                                                                 '(e.g., '
                                                                 'surprise, '
                                                                 'disgust), '
                                                                 'increasing '
                                                                 'share '
                                                                 'likelihood.',
                                                                 'Automated '
                                                                 'accounts '
                                                                 '(bots) play '
                                                                 'a '
                                                                 'disproportionate '
                                                                 'role in '
                                                                 'early '
                                                                 'amplification: '
                                                                 'analysis of '
                                                                 '14 million '
                                                                 'tweets '
                                                                 'around the '
                                                                 '2016 U.S. '
                                                                 'election '
                                                                 'found social '
                                                                 'bots '
                                                                 'aggressively '
                                                                 'spread links '
                                                                 'from '
                                                                 'low‑credibility '
                                                                 'sources in '
                                                                 'the crucial '
                                                                 'early '
                                                                 'moments to '
                                                                 'jumpstart '
                                                                 'viral '
                                                                 'momentum '
                                                                 '(Shao et '
                                                                 'al., 2018).',
                                                                 'Demographic '
                                                                 'skew in '
                                                                 'sharing: '
                                                                 'Facebook '
                                                                 'activity '
                                                                 'during the '
                                                                 '2016 U.S. '
                                                                 'election '
                                                                 'showed a '
                                                                 'small '
                                                                 'fraction of '
                                                                 'users '
                                                                 'accounted '
                                                                 'for the '
                                                                 'majority of '
                                                                 'fake‑news '
                                                                 'shares; '
                                                                 'Americans '
                                                                 'over 65 '
                                                                 'shared '
                                                                 'several '
                                                                 'times more '
                                                                 'fake news '
                                                                 'articles on '
                                                                 'average than '
                                                                 'younger '
                                                                 'groups '
                                                                 '(Guess et '
                                                                 'al., 2019).',
                                                                 'Systemic '
                                                                 'supply‑side '
                                                                 'failures '
                                                                 '(scientific '
                                                                 'communication): '
                                                                 'interviews '
                                                                 'with '
                                                                 'scientists '
                                                                 'and health '
                                                                 'communicators '
                                                                 'during '
                                                                 'COVID‑19 '
                                                                 'identified '
                                                                 'publication '
                                                                 'of '
                                                                 'low‑quality '
                                                                 'or biased '
                                                                 'research, '
                                                                 'limited '
                                                                 'public '
                                                                 'access to '
                                                                 'high‑quality '
                                                                 'findings, '
                                                                 'and '
                                                                 'insufficient '
                                                                 'public '
                                                                 'understanding '
                                                                 'of science '
                                                                 'as drivers '
                                                                 'that seed '
                                                                 'and sustain '
                                                                 'misinformation '
                                                                 '(Parker et '
                                                                 'al., 2021).',
                                                                 'Speed '
                                                                 'advantage of '
                                                                 'falsehoods '
                                                                 'vs. '
                                                                 'corrective '
                                                                 'responses: '
                                                                 'viral false '
                                                                 'news spreads '
                                                                 'roughly 6× '
                                                                 'faster than '
                                                                 'truth '
                                                                 '(benchmark). '
                                                                 'Fact‑check '
                                                                 'response '
                                                                 'time '
                                                                 'improved '
                                                                 'from ~30–45 '
                                                                 'min '
                                                                 '(earlier) to '
                                                                 '~15 min (by '
                                                                 '2023), but '
                                                                 'even a '
                                                                 '15‑minute '
                                                                 'lag can be '
                                                                 'sufficient '
                                                                 'for false '
                                                                 'narratives '
                                                                 'to embed and '
                                                                 'shape '
                                                                 'longer‑term '
                                                                 'beliefs.',
                                                                 'Cognitive/behavioral '
                                                                 'factors: '
                                                                 'many people '
                                                                 'do not '
                                                                 'intend to '
                                                                 'spread '
                                                                 'misinformation '
                                                                 'but fail to '
                                                                 'consider '
                                                                 'accuracy '
                                                                 'before '
                                                                 'sharing; '
                                                                 'prompting '
                                                                 'users to '
                                                                 'consider '
                                                                 'accuracy '
                                                                 'significantly '
                                                                 'reduced '
                                                                 'sharing of '
                                                                 'false '
                                                                 'headlines '
                                                                 '(Pennycook '
                                                                 'et al., '
                                                                 '2021). Lack '
                                                                 'of attention '
                                                                 'to accuracy '
                                                                 'at the '
                                                                 'moment of '
                                                                 'sharing '
                                                                 'helps '
                                                                 'misinformation '
                                                                 'persist.',
                                                                 'Familiarity/repetition '
                                                                 'and “noise”: '
                                                                 'repeated '
                                                                 'exposure '
                                                                 'increases '
                                                                 'perceived '
                                                                 'truthfulness '
                                                                 '(“familiarity '
                                                                 'effect”); '
                                                                 'high‑volume '
                                                                 'bot activity '
                                                                 'can create '
                                                                 'information '
                                                                 'overload, '
                                                                 'increasing '
                                                                 'chances that '
                                                                 'repeated '
                                                                 'falsehoods '
                                                                 'stick.',
                                                                 '“Liar’s '
                                                                 'dividend”: '
                                                                 'the '
                                                                 'existence of '
                                                                 'fakes '
                                                                 '(deepfakes, '
                                                                 'synthetic '
                                                                 'content) can '
                                                                 'allow bad '
                                                                 'actors to '
                                                                 'dismiss '
                                                                 'authentic '
                                                                 'material as '
                                                                 'fake later, '
                                                                 'undermining '
                                                                 'trust and '
                                                                 'making it '
                                                                 'easier for '
                                                                 'initial '
                                                                 'false claims '
                                                                 'or '
                                                                 'counter‑claims '
                                                                 'to persist.',
                                                                 'Credibility '
                                                                 'conferred by '
                                                                 'synthetic '
                                                                 'identities '
                                                                 'and '
                                                                 'coordinated '
                                                                 'networks: '
                                                                 'millions of '
                                                                 'AI‑generated '
                                                                 'personas and '
                                                                 'coordinated '
                                                                 'botnets '
                                                                 'create the '
                                                                 'illusion of '
                                                                 'consensus or '
                                                                 'grassroots '
                                                                 'support, '
                                                                 'lending '
                                                                 'apparent '
                                                                 'legitimacy '
                                                                 'to initial '
                                                                 'false claims '
                                                                 'and making '
                                                                 'them harder '
                                                                 'to dislodge.',
                                                                 'Microtargeting '
                                                                 'and '
                                                                 'personalization: '
                                                                 'AI‑enhanced '
                                                                 'microtargeting '
                                                                 'increases '
                                                                 'persuasive '
                                                                 'impact of '
                                                                 'tailored '
                                                                 'false '
                                                                 'messages; '
                                                                 'personalized '
                                                                 'misinformation '
                                                                 'is more '
                                                                 'effective at '
                                                                 'persuading '
                                                                 'individuals '
                                                                 'than '
                                                                 'one‑size‑fits‑all '
                                                                 'propaganda.'],
              'present_day_repetition_examples_2024_2025_with_quotes_and_sources': []},
 'evidence_store': [['No search results',
                     'No search results',
                     'No content on this page relates to an FDA emergency use '
                     'authorization for hydroxychloroquine for COVID-19 '
                     '(2020). The page is a general USA.gov homepage with '
                     'links to government topics and services but contains no '
                     'EUA statement or related details.',
                     'No search results',
                     'No search results',
                     'No relevant content found on the provided page for the '
                     'query "altmetric score hydroxychloroquine 2020 study."\n'
                     '\n'
                     'Page content is Google Scholar interface/navigation text '
                     '(language options, search fields, links) and contains no '
                     'information, numeric data, or mention of altmetric '
                     'scores, hydroxychloroquine, or any 2020 study.',
                     'No search results'],
                    ['- Date: March 28, 2020 — FDA issued an Emergency Use '
                     'Authorization (EUA).\n'
                     '\n'
                     '- Products covered: hydroxychloroquine sulfate and '
                     'chloroquine phosphate donated to the Strategic National '
                     'Stockpile (SNS).\n'
                     '\n'
                     '- Authorized use: to be distributed from the SNS to '
                     'states and used for certain hospitalized patients with '
                     'COVID-19 — specifically for adolescent and adult '
                     'patients hospitalized with COVID-19, as appropriate, '
                     'when a clinical trial is not available or feasible.\n'
                     '\n'
                     '- EUA requirements: fact sheets providing important '
                     'information about using chloroquine phosphate and '
                     'hydroxychloroquine sulfate in treating COVID-19 must be '
                     'made available to health care providers and patients, '
                     'including the known risks and drug interactions.\n'
                     '\n'
                     '- Distribution logistics: the SNS, managed by the '
                     'Assistant Secretary for Preparedness and Response '
                     '(ASPR), will work with the Federal Emergency Management '
                     'Agency (FEMA) to ship donated doses to states.',
                     'No search results',
                     'Title: FDA Guidance for Emergency Use of Chloroquine '
                     'Phosphate and Hydroxychloroquine Sulfate\n'
                     '\n'
                     'Audience: Licensed prescribers and dispensers\n'
                     '\n'
                     'Key points:\n'
                     '- This communication informs licensed prescribers and '
                     'dispensers of a recent FDA guidance authorizing '
                     'emergency use of chloroquine phosphate and '
                     'hydroxychloroquine sulfate.\n'
                     '- The authorization details are described in the Scope '
                     'of Authorization (Section II) of the FDA letter '
                     'referenced by the communication; the emergency use is '
                     'for the treatment of COVID-19.\n'
                     '- LARA (Michigan Department of Licensing and Regulatory '
                     'Affairs) acknowledges the role of prescribers and '
                     'dispensers and urges responsible prescribing and '
                     'dispensing practices.\n'
                     '- Signed by: Debra Gagliardi, Director, Bureau of '
                     'Professional Licensing.',
                     '- Date: 06/15/2020 — FDA revokes the emergency use '
                     'authorization (EUA) for chloroquine phosphate and '
                     'hydroxychloroquine sulfate.\n'
                     '\n'
                     '- Scope of revoked EUA: EUA had allowed chloroquine and '
                     'hydroxychloroquine donated to the Strategic National '
                     'Stockpile to be used to treat certain hospitalized '
                     'patients with COVID-19 when a clinical trial was '
                     'unavailable or participation in a clinical trial was not '
                     'feasible.\n'
                     '\n'
                     '- Reason for revocation:\n'
                     '  - The FDA determined the legal criteria for issuing an '
                     'EUA are no longer met.\n'
                     '  - Based on ongoing analysis and emerging scientific '
                     'data, chloroquine and hydroxychloroquine are unlikely to '
                     'be effective in treating COVID-19 for the authorized '
                     'uses.\n'
                     '  - Ongoing serious cardiac adverse events and other '
                     'potential serious side effects mean the known and '
                     'potential benefits no longer outweigh the known and '
                     'potential risks (the statutory standard for an EUA).\n'
                     '\n'
                     '- Evidence cited:\n'
                     '  - Recent results from a large randomized clinical '
                     'trial in hospitalized patients (a population similar to '
                     'the authorized population) demonstrated '
                     'hydroxychloroquine showed no benefit on mortality or in '
                     'speeding recovery.\n'
                     '  - Data indicate suggested dosing regimens for '
                     'chloroquine and hydroxychloroquine are unlikely to kill '
                     'or inhibit the virus that causes COVID-19.\n'
                     '  - The totality of scientific evidence available '
                     'indicates a lack of benefit.\n'
                     '\n'
                     '- Procedural/contextual details:\n'
                     '  - The Biomedical Advanced Research and Development '
                     'Authority (BARDA) originally requested the EUA; the FDA '
                     'granted the EUA on March 28, 2020.\n'
                     '  - In consultation with the FDA, BARDA sent a letter to '
                     'the FDA requesting revocation of the EUA based on '
                     'up-to-date science and data.\n'
                     '  - FDA statements note the agency will continue to '
                     'review emerging information associated with emergency '
                     'uses and make changes as appropriate.\n'
                     '\n'
                     '- Regulatory note: Chloroquine and hydroxychloroquine '
                     'remain FDA-approved for other indications (malaria; '
                     'hydroxychloroquine also for certain autoimmune '
                     'conditions) and may be prescribed off-label by '
                     'physicians according to their judgment.',
                     '- Title: Authorizations and Revocation of Emergency Use '
                     'of Drugs During the COVID-19 Pandemic; Availability\n'
                     '- Agency: Food and Drug Administration (FDA), Department '
                     'of Health and Human Services (HHS)\n'
                     '- Docket No.: FDA-2020-N-1729\n'
                     '- Document Number: 2020-20041\n'
                     '- Federal Register citation: 85 FR 56231\n'
                     '- Pages: 56231–56264\n'
                     '- Publication date: September 11, 2020\n'
                     '- EUA issued to BARDA: oral formulations of chloroquine '
                     'phosphate and hydroxychloroquine sulfate\n'
                     '  - EUA effective date: March 28, 2020\n'
                     '- EUA revocation for BARDA (chloroquine phosphate and '
                     'hydroxychloroquine sulfate)\n'
                     '  - Revocation effective date: June 15, 2020\n'
                     '  - Legal authority cited: FD&C Act section 564 — '
                     'revocation pursuant to section 564(g)(2)\n'
                     '  - Reason given: FDA concluded the criteria for '
                     'issuance under section 564(c)(2) are no longer met. '
                     'Based on review of new information and reevaluation of '
                     'prior information, FDA concluded it is no longer '
                     'reasonable to believe that (1) oral chloroquine '
                     'phosphate and hydroxychloroquine sulfate may be '
                     'effective in treating COVID-19 for the uses authorized '
                     'in the EUA, and (2) the known and potential benefits of '
                     'these products outweigh their known and potential risks '
                     'for those uses.\n'
                     '- Notice states the Authorizations and the revocation '
                     '(including explanations of reasons) are reprinted in the '
                     'document and an electronic version is available via FDA.',
                     '- Document: Federal Register Notice — "Authorizations '
                     'and Revocation of Emergency Use of Drugs During the '
                     'COVID-19 Pandemic; Availability"  \n'
                     '  - Document number: 2020-20041  \n'
                     '  - Citation: 85 FR 56231  \n'
                     '  - Docket No.: FDA-2020-N-1729  \n'
                     '  - Agency: Food and Drug Administration (FDA), '
                     'Department of Health and Human Services (HHS)  \n'
                     '  - Publication date: September 11, 2020  \n'
                     '  - Pages: 56231–56264\n'
                     '\n'
                     '- EUA for chloroquine/hydroxychloroquine (BARDA)  \n'
                     '  - Product authorized: Oral formulations of chloroquine '
                     'phosphate and hydroxychloroquine sulfate  \n'
                     '  - EUA issued to: HHS Biomedical Advanced Research and '
                     'Development Authority (BARDA)  \n'
                     '  - EUA effective date (authorization): March 28, '
                     '2020  \n'
                     '  - EUA revoked (revocation effective date): June 15, '
                     '2020  \n'
                     '  - Revocation published in this Federal Register notice '
                     '(see document above)\n'
                     '\n'
                     '- Legal/statutory basis cited  \n'
                     '  - Authority: Section 564 of the Federal Food, Drug, '
                     'and Cosmetic Act (21 U.S.C. 360bbb-3)  \n'
                     '  - Revocation authority referenced: section 564(g)(2) '
                     'and criteria in section 564(c)(2) of the FD&C Act\n'
                     '\n'
                     '- Reason for revocation (as stated in the notice)  \n'
                     '  - After review of new information and reevaluation of '
                     'evidence available when the EUA was issued, FDA '
                     'concluded:  \n'
                     '    - It is no longer reasonable to believe oral '
                     'chloroquine phosphate and hydroxychloroquine sulfate may '
                     'be effective for the authorized uses in treating '
                     'COVID-19.  \n'
                     '    - The known and potential benefits of these '
                     'products, for those authorized uses, no longer outweigh '
                     'their known and potential risks.  \n'
                     '  - Conclusion: the criteria for issuance of the EUA '
                     'were no longer met; therefore FDA revoked the EUA for '
                     'BARDA’s oral formulations of chloroquine phosphate and '
                     'hydroxychloroquine sulfate.\n'
                     '\n'
                     '- Related timing/context (from the notice)  \n'
                     '  - Secretary of HHS determination of public health '
                     'emergency involving novel coronavirus: February 4, 2020 '
                     '(Federal Register notice 85 FR 7316 published Feb 7, '
                     '2020).  \n'
                     '  - Secretary of HHS declaration justifying EUA issuance '
                     'for drugs/biologics during COVID-19: March 27, 2020 '
                     '(Federal Register notice 85 FR 18250 published Apr 1, '
                     '2020).\n'
                     '\n'
                     '- Electronic access  \n'
                     '  - Full document and Authorizations/revocation '
                     'available via FDA emergency use authorization web page '
                     '(link provided in the notice).'],
                    ['Scope and objective\n'
                     '- Systematic review and meta-analysis of repurposed '
                     'hydroxychloroquine (HCQ) and chloroquine (CQ) in '
                     'hospitalized COVID‑19 patients, with emphasis on '
                     'efficacy and cardiovascular (QTc) effects.\n'
                     '\n'
                     'Search and selection\n'
                     '- Databases searched: Google Scholar, PubMed, Scopus, '
                     'Web of Science, ClinicalTrials.gov.\n'
                     '- Search period: December 10, 2022 to February 15, '
                     '2024.\n'
                     '- Screening yield: 1,077 records screened; 30 full‑text '
                     'articles assessed; 9 studies included.\n'
                     '\n'
                     'Eligibility criteria (as reported)\n'
                     '- Population: hospitalized patients with confirmed or '
                     'suspected COVID‑19.\n'
                     '- Intervention: antimalarial drugs (HCQ or CQ), alone or '
                     'with azithromycin.\n'
                     '- Outcomes: viral negative conversion, mortality, ECG '
                     'surveillance, QTc interval changes, adverse cardiac '
                     'events.\n'
                     '\n'
                     'Included studies (summary from Table 1; n = 9)\n'
                     '- Overall: 9 studies included (3 retrospective studies, '
                     '6 randomized trials or trial reports, and 1 case series '
                     'reported across the review).\n'
                     '- Reported study-type and sample-size breakdown (as '
                     'reported in abstract):\n'
                     '  - Three retrospective studies: 386 patients with '
                     'baseline and follow‑up ECG.\n'
                     '  - Four randomized trials of HCQ: 283 patients in total '
                     '(HCQ with standard care/azithromycin = 188; standard '
                     'care/placebo = 95).\n'
                     '  - One randomized trial of CQ: 81 patients (high‑dose '
                     'CQ = 41; low‑dose CQ = 40).\n'
                     '  - One case series: 98 patients (HCQ = 10; azithromycin '
                     '= 27; HCQ + azithromycin = 61).\n'
                     '\n'
                     'Key trial-level findings and numeric results (as '
                     'reported in the review’s Table 1 and text)\n'
                     '- Eveleens Maarse BC et al.\n'
                     '  - HCQ 400 mg at multiple timepoints (0, 12, 24, 48, '
                     '72, 96 hr).\n'
                     '  - Result: No significant correlation between HCQ and '
                     'RR-, QRS-, or QTcF‑intervals (P > 0.05).\n'
                     '  - Conclusion: At plasma concentrations up to 200 '
                     'ng/mL, HCQ had no effect on ventricular repolarization '
                     'including QTcF and T‑wave shape.\n'
                     '- Chorin E. et al.\n'
                     '  - HCQ 400 mg twice daily (BD) day 1, then 200 mg BD ×4 '
                     'days.\n'
                     '  - Result: Severe new QTc prolongation to ≥500 ms in '
                     '23% of cases.\n'
                     '  - Conclusion: HCQ markedly lengthens QTc in COVID‑19 '
                     'patients.\n'
                     '- Tang W. et al.\n'
                     '  - HCQ 1,200 mg once daily (OD) for 3 days then 800 mg '
                     'OD for 2–3 weeks (regimen reported).\n'
                     '  - Result: QTc prolongation and cardiac arrhythmia '
                     'reported; no significant difference in viral negative '
                     'conversion versus standard care.\n'
                     '- Borba MGS. et al. (CQ trial)\n'
                     '  - High‑dose CQ 2.7 g OD/10 days (reported) with '
                     'azithromycin 500 g (table entry).\n'
                     '  - Result: Ventricular arrhythmia or QTc > 500 ms '
                     'reported at 28 days; higher-dose group had increased '
                     'occurrence of QTc > 500 ms.\n'
                     '  - Conclusion: High‑dose CQ not recommended for '
                     'critically ill patients.\n'
                     '- van den Broek et al.\n'
                     '  - CQ 600 mg OD/5 days (reported).\n'
                     '  - Result: Mean QTc prolongation 35 ms (95% CI 28–43 '
                     'ms).\n'
                     '  - Conclusion: Chloroquine significantly prolongs QTc '
                     'interval.\n'
                     '- Bessière F. et al.\n'
                     '  - HCQ 200 mg BD for 10 days (reported).\n'
                     '  - Result: 93% of patients displayed an increase in '
                     'QTc.\n'
                     '  - Conclusion: QTc intervals increased in >90% of '
                     'patients.\n'
                     '- Ramireddy et al.\n'
                     '  - HCQ with azithromycin (regimen reported).\n'
                     '  - Result: Baseline mean QTc 448 ± 29 ms increased to '
                     '459 ± 36 ms (P = 0.005); critical QTc prolongation '
                     'present in 12% of patients overall.\n'
                     '- Cipriani et al.\n'
                     '  - HCQ 200 mg BD for 3 days plus azithromycin 500 mg '
                     '(reported).\n'
                     '  - Result: QTc interval longer after treatment (p = '
                     '0.02).\n'
                     '  - Conclusion: Azithromycin + HCQ prolong QTc, '
                     'especially with high transaminase levels.\n'
                     '- Bun SS et al.\n'
                     '  - HCQ 200 mg three times daily (TID) for 10 days '
                     '(reported).\n'
                     '  - Result: Average automated QTc prolonged after 48 '
                     'hr.\n'
                     '  - Conclusion: Combination therapy with HCQ/AZT may be '
                     'used in inpatients with lower respiratory tract '
                     'infection but QTc increases observed.\n'
                     '\n'
                     'Aggregate and outcome statements (as reported)\n'
                     '- Reported range of significant QTc prolongation across '
                     'included studies: 12% to 93% of patients.\n'
                     '- One paragraph reports: when given HCQ with standard '
                     'therapy, 30% of patients experienced adverse events '
                     'versus 9% in control (adverse events included diarrhea, '
                     'impaired vision, gastrointestinal issues).\n'
                     '- Tang W. trial found no difference in viral negative '
                     'conversion between HCQ and standard of care.\n'
                     '- High‑dose CQ associated with higher rates of QTc > 500 '
                     'ms and adverse events; not recommended for severe '
                     'cases.\n'
                     '\n'
                     'Risk of bias and methodological notes (as reported)\n'
                     '- Modified Newcastle‑Ottawa Quality Assessment applied; '
                     'table shows score items per study (ascertainment of '
                     'exposure, outcomes assessment, length of follow‑up, loss '
                     'to follow‑up rate), with most items marked as 1.\n'
                     '- Review reports low risk for random sequence generation '
                     'and attrition bias in most RCTs, but potential risks for '
                     'allocation concealment, performance, detection, and '
                     'reporting bias.\n'
                     '\n'
                     'Authors’ conclusions relevant to hospitalized randomized '
                     'trials (as reported)\n'
                     '- The available RCTs and retrospective studies did not '
                     'demonstrate therapeutic benefit of HCQ (or CQ at tested '
                     'regimens) for hospitalized COVID‑19 patients.\n'
                     '- HCQ and CQ were associated with clinically significant '
                     'QTc prolongation; continuous ECG surveillance and '
                     'individualized risk assessment are recommended during '
                     'treatment.\n'
                     '- High‑dose chloroquine increased risk of QTc > 500 ms '
                     'and related adverse outcomes and is not recommended for '
                     'critically ill patients.\n'
                     '\n'
                     'Limitations noted (as reported)\n'
                     '- Early study terminations, potential detection and '
                     'performance bias, inclusion of non‑peer‑reviewed studies '
                     'affecting evidence quality.\n'
                     '- Heterogeneity of studies limited pooled statistical '
                     'analyses for some outcomes (e.g., QTc > 500 ms).\n'
                     '\n'
                     'Primary numeric synthesis points for meta-analysis '
                     'subtask (reported in the article)\n'
                     '- Included studies: 9 total; RCTs reported: four HCQ '
                     'randomized trials totaling 283 patients (188 in '
                     'HCQ/azithromycin arms, 95 in control/plbo) plus one CQ '
                     'randomized trial with 81 patients (41 high dose, 40 low '
                     'dose).\n'
                     '- Observed QTc effects: mean CQ QTc prolongation 35 ms '
                     '(95% CI 28–43 ms) in one trial; QTc increases ranging '
                     'from small mean increases (e.g., 448 ±29 → 459 ±36 ms, P '
                     '= 0.005) to high proportions of patients with QTc '
                     'elevation (12% to 93%, depending on study).\n'
                     '\n'
                     'Core practical implication (as reported)\n'
                     '- No demonstrated clinical efficacy of HCQ/CQ in '
                     'hospitalized COVID‑19 patients from the included RCTs; '
                     'notable risk of QTc prolongation mandates ECG monitoring '
                     'when these drugs are used.',
                     '- Pradelle et al. (published January 2024) presented '
                     'meta-analyses claiming that hydroxychloroquine (HCQ) '
                     'compassionate use during COVID-19’s first wave was '
                     'associated with more than 16,990 deaths across Belgium, '
                     'France, the USA, Spain, Turkey, and Italy. The Pradelle '
                     'et al. publication was later retracted for “lack of '
                     'sufficiently reliable data” and “questionable '
                     'assumptions.” \n'
                     '\n'
                     '- The Pradelle analysis estimated in-hospital '
                     'HCQ-related mortality using odds ratios (ORs) borrowed '
                     'from Axfors et al.’s prior meta-analyses. Those ORs were '
                     'mainly derived from high-dose randomized controlled '
                     'trials (RCTs), but Pradelle et al. applied the same '
                     'effect size across all patient groups regardless of '
                     'actual dose received (no dose-subgroup corrections).\n'
                     '\n'
                     '- Methodological criticisms of Pradelle et al. relevant '
                     'to RCT-derived outcomes:\n'
                     '  - Misapplication of effect sizes from high-dose RCTs '
                     'to lower-dose regimens without accounting for '
                     'dose-dependency.\n'
                     '  - Absence of sensitivity analyses and subgroup (dose) '
                     'estimations to test robustness.\n'
                     '  - Statistical conclusions (increased mortality) '
                     'depended heavily on a single large study in sensitivity '
                     'analyses.\n'
                     '\n'
                     '- Reanalysis findings reported in the critique:\n'
                     '  - Lower-dose HCQ regimens showed no clear evidence of '
                     'increased mortality.\n'
                     '  - Only higher-dose regimens were associated with a '
                     'possible increase in mortality risk.',
                     'No relevant content found.\n'
                     '\n'
                     '- The page contains no mention of "hydroxychloroquine" '
                     '(or "hydroxy") and no listing or description of a '
                     '2023–2025 large observational cohort study of '
                     'hydroxychloroquine use and mortality or cardiac adverse '
                     'events in hospitalized COVID-19 patients.',
                     'No relevant information found. The page contains no data '
                     'or sections about hydroxychloroquine or chloroquine '
                     'safety, QT prolongation, arrhythmia, or adverse drug '
                     'interactions in COVID-19 patients (2023–2025).',
                     'Objective\n'
                     '- Meta-analysis of randomized controlled trials (RCTs) '
                     'studying hydroxychloroquine (HCQ) as pre-exposure '
                     'prophylaxis (PrEP) for COVID-19 in healthcare workers '
                     '(HCWs).\n'
                     '\n'
                     'Search and selection\n'
                     '- Databases searched: PubMed/Medline and Ovid/EMBASE '
                     'through 14 March 2023.\n'
                     '- Eligibility: Phase II or III RCTs of HCQ for PrEP in '
                     'HCWs at moderate–high exposure risk.\n'
                     '- Studies included: 10 RCTs (after screening 350 unique '
                     'records; 11 full-text assessed, 1 excluded for non-HCW '
                     'population).\n'
                     '\n'
                     'Study population and interventions\n'
                     '- Total randomized participants: 5,079 (2,961 randomized '
                     'to HCQ).\n'
                     '- Population: HCWs (definitions broad; included first '
                     'responders).\n'
                     '- Follow-up durations across trials: 28 to 180 days.\n'
                     '- HCQ dosing schemes varied: daily dosing from 200 to '
                     '600 mg (with or without loading doses), once or twice '
                     'weekly, or once every 3 weeks. Trials with multiple HCQ '
                     'arms had arms pooled for analysis.\n'
                     '\n'
                     'Outcomes and definitions\n'
                     '- Primary efficacy outcome: PCR-confirmed SARS-CoV-2 '
                     'infection (COVID-19-like symptoms + positive PCR).\n'
                     '- Secondary efficacy outcome: suspected/probable '
                     'SARS-CoV-2 infection (symptoms without confirmatory '
                     'PCR).\n'
                     '- Primary safety outcome: incidence of adverse events.\n'
                     '\n'
                     'Analysis methods\n'
                     '- Bayesian logistic regression meta-analysis using '
                     'fixed-effects and random-effects models; random-effects '
                     'chosen based on model fit.\n'
                     '- Non-informative priors; Markov chain Monte Carlo used '
                     'for posterior estimation.\n'
                     '- Posterior probabilities calculated for OR < 1 and < '
                     '0.5 (efficacy) and OR > 2 (safety).\n'
                     '- Heterogeneity metrics reported: I2 and SD of random '
                     'effects.\n'
                     '- GRADE used to assess certainty of evidence.\n'
                     '\n'
                     'Key numerical results\n'
                     '- Overall event rates:\n'
                     '  - PCR-confirmed infection: 3.4% (171 of 5,039).\n'
                     '  - Suspected (not lab-confirmed) infection: 5.6% (230 '
                     'of 4,087).\n'
                     '- PCR-confirmed SARS-CoV-2 infection:\n'
                     '  - Odds ratio (OR) HCQ vs placebo: 0.92\n'
                     '  - 95% credible interval (CI): 0.58 to 1.37\n'
                     '  - GRADE: moderate certainty\n'
                     '  - Bayesian posterior probability OR < 1: 0.67\n'
                     '  - Bayesian posterior probability OR < 0.5: 0.009\n'
                     '- Suspected/probable SARS-CoV-2 infection:\n'
                     '  - OR HCQ vs placebo: 0.78\n'
                     '  - 95% CI: 0.57 to 1.10\n'
                     '  - GRADE: moderate certainty\n'
                     '- Adverse events:\n'
                     '  - OR HCQ vs placebo: 1.35\n'
                     '  - 95% CI: 1.03 to 1.73 (statistically significant '
                     'increase)\n'
                     '  - GRADE: moderate certainty\n'
                     '  - Bayesian posterior probability OR > 2: 0.004\n'
                     '- Heterogeneity:\n'
                     '  - I2 values: 0% (confirmed), 0% (suspected), 43% '
                     '(adverse events)\n'
                     '  - Estimated SD of random effects: 0.39 (confirmed), '
                     '0.26 (suspected), 0.45 (adverse events)\n'
                     '- Publication bias: funnel plots and Egger’s tests '
                     'showed no indication of publication bias (Egger’s '
                     'p-values: 0.308, 0.305, 0.794 for confirmed, suspected, '
                     'adverse events respectively).\n'
                     '\n'
                     'Conclusions\n'
                     '- HCQ, compared with placebo, did not significantly '
                     'reduce risk of PCR-confirmed or suspected SARS-CoV-2 '
                     'infection in HCWs.\n'
                     '- HCQ was associated with a statistically significant '
                     'increase in adverse events.\n'
                     '- Authors’ recommendation: HCQ should not be used for '
                     'pre-exposure prophylaxis in the healthcare worker '
                     'population.\n'
                     '\n'
                     'Other relevant details\n'
                     '- Protocol registered: PROSPERO CRD42021285093.\n'
                     '- Geographic coverage of included trials: USA, Canada, '
                     'Mexico, India, Spain, Bolivia, Venezuela, Peru, '
                     'Pakistan.\n'
                     '- Limitations noted by authors: varied dosing regimens '
                     'across trials (dose effects not assessed), many '
                     'individual trials underpowered, limited subgroup '
                     'analyses due to aggregate data.',
                     'Extracted content relevant to hydroxychloroquine / '
                     'chloroquine (2023–2025 guidance context) from the page:\n'
                     '\n'
                     '- Location: "Other candidate antiviral therapies"\n'
                     '  - "Chloroquine (CQ) or hydroxychloroquine (HCQ)\n'
                     '    + Based on the arm of the RECOVERY trial showing no '
                     'clinical benefit, and other clinical data with '
                     'cardiotoxicity concerns"\n'
                     '\n'
                     'Note: The page does not present explicit WHO or NIH '
                     'guidance updates (2023–2025) about '
                     'chloroquine/hydroxychloroquine beyond the above '
                     'statement attributing lack of benefit and cardiotoxicity '
                     'concerns to RECOVERY and other clinical data.',
                     'No search results',
                     '- A Government Accountability Office (GAO) report '
                     'criticized HHS leadership and coordination in handling '
                     'public health emergencies, specifically its management '
                     'of the Strategic National Stockpile (SNS).\n'
                     '- The GAO scrutiny resulted in recommendations for '
                     'improvement to SNS management.\n'
                     '- The page provides no numeric data and includes no '
                     'information about distribution or handling of donated '
                     'hydroxychloroquine in 2020.',
                     'No relevant content found. The page contains reporting '
                     'about an H3N2 flu surge (influenza activity, '
                     'case/hospitalization/death estimates, vaccine mismatch) '
                     'but does not include any investigative journalism pieces '
                     'from 2023–2025 about the 2020 hydroxychloroquine EUA, '
                     'nor information on decision-making, political influence, '
                     'or communications around that EUA.',
                     'No relevant content found',
                     'No content on this page pertains to 2023–2025 policy '
                     'analyses or legal reviews that reinterpret FDA EUA '
                     'criteria as applied to hydroxychloroquine in 2020. No '
                     'relevant material was found.',
                     'No search results'],
                    ['- On March 28, the FDA issued an Emergency Use '
                     'Authorization (EUA) for hydroxychloroquine to be used in '
                     'hospitals to treat novel coronavirus (COVID-19) '
                     'patients.\n'
                     '\n'
                     '- Hydroxychloroquine (Plaquenil) is described as an '
                     'immunosuppressant/anti-inflammatory drug used to treat '
                     'lupus symptoms (e.g., muscle and joint pain, skin '
                     'rashes, fatigue, fever). (Personal dosage example in the '
                     'article: 200 milligrams twice a day.)\n'
                     '\n'
                     '- Preliminary international research suggested '
                     'hydroxychloroquine might speed recovery in severely ill '
                     'COVID-19 patients, but a study published in the New '
                     'England Journal of Medicine showed it did not.\n'
                     '\n'
                     '- The FDA issued a caution against using '
                     'hydroxychloroquine or chloroquine to treat COVID-19 '
                     'outside a hospital setting or a clinical trial because '
                     'of potential side effects, including heart arrhythmia.',
                     'No search results',
                     'No search results',
                     'No search results',
                     '- Hydroxychloroquine is an anti-malaria drug.  \n'
                     '- The U.S. Food and Drug Administration (FDA) initially '
                     'listed hydroxychloroquine as a potential treatment and '
                     'prophylaxis for hospitalized COVID-19 patients.  \n'
                     '- Following reports of cardiac adverse events in '
                     'COVID-19 patients who had received hydroxychloroquine, '
                     'the FDA issued statements cautioning against using the '
                     'drug outside of a hospital or clinical trial.  \n'
                     '- By June 2020 the FDA had revoked hydroxychloroquine’s '
                     'emergency use authorization (EUA).  \n'
                     '- A press conference by “America’s Frontline Doctors” '
                     'held outside the Supreme Court building in late July '
                     '2020 (July 28, 2020) promoted hydroxychloroquine as a '
                     'cure for COVID-19; Dr. Stella Immanuel specifically '
                     'named hydroxychloroquine, zinc, and Zithromax.  \n'
                     '- Within two weeks of that press conference, at least 42 '
                     'podcast episodes shared claims about '
                     'hydroxychloroquine’s efficacy.  \n'
                     '- Researchers in this analysis began coding '
                     'hydroxychloroquine-related claims only after the FDA '
                     'revoked the drug’s EUA.  \n'
                     '- In the dataset examined, podcast conversations about '
                     'hydroxychloroquine “skyrocketed” in the summer of 2020 '
                     'and remained a constant feature throughout the study '
                     'period.',
                     'No relevant content found. The provided page (World '
                     'Economic Forum Annual Meeting / Davos 2024) contains no '
                     'information about "hydroxychloroquine," "FDA '
                     'authorized," or a 2024 high-engagement Facebook post.',
                     'No search results',
                     'No search results',
                     'No search results',
                     'No relevant content found',
                     'No search results',
                     'No search results'],
                    ['No relevant content found',
                     'No content relevant to "2021–2025 analyses of media '
                     'inertia and the mechanisms that sustain early narratives '
                     'in news coverage" was found on the provided page. The '
                     'page contains a staff profile (Professor Jamie Morgan), '
                     'lists of publications and articles on economics, '
                     'climate, technology, and related topics, and some '
                     'news/blog post titles, but none addressing media '
                     'inertia, early news narratives, or analyses dated '
                     '2021–2025.',
                     'No relevant content found.\n'
                     '\n'
                     'This page contains only site navigation and boilerplate '
                     '(login prompts, cookie notices, membership/login links, '
                     'password/account instructions, and general site tools). '
                     'It contains no information, data, or findings about '
                     '2021–2025 research on how the attention economy and '
                     'journalistic incentives favor early sensational frames. '
                     'No numeric data present.',
                     'Findings from the provided web page (arXiv Computer '
                     'Science new listings):\n'
                     '\n'
                     '- No items on the page match the target subtask topics. '
                     'I found no entries related to:\n'
                     '  - "anchoring"\n'
                     '  - "belief perseverance"\n'
                     '  - "continued influence effect"\n'
                     '\n'
                     '- The page metadata (for context within the scraped '
                     'content):\n'
                     '  - Showing new listings for Friday, 19 December 2025\n'
                     '  - Total of 839 entries; showing new submissions (502 '
                     'of 502)\n'
                     '\n'
                     'No numeric or bibliographic records relevant to '
                     '2021–2025 cognitive science literature on anchoring, '
                     'belief perseverance, or the continued influence effect '
                     'were present on this page.',
                     'Summary of relevant content for subtask "2021–2025 '
                     'empirical studies testing the effectiveness of '
                     'corrections, retractions, and qualifiers in changing '
                     'public beliefs":\n'
                     '\n'
                     '- No empirical studies (2021–2025) that test the '
                     'effectiveness of corrections, retractions, or qualifiers '
                     'in changing public beliefs were found on this page.\n'
                     '\n'
                     'Related items on the page (not meeting the subtask '
                     'criteria but topically adjacent):\n'
                     '- Title: "HASHTAGS E BOTS SOCIAIS NO TWITTER: A ELEIÇÃO '
                     'PRESIDENCIAL DE 2022"\n'
                     '  - Author/date: Jefferson Rodrigo de Almeida Torquato — '
                     'Date: 21/03/2025\n'
                     '  - Content: Dissertation examining how political '
                     'discourse was structured and circulated on Twitter '
                     'during the 2022 presidential election; grounded in '
                     'materialist Discourse Analysis; focuses on hashtags, '
                     'social bots, discursive memory and manipulation. Method: '
                     'discourse/critical analysis (not an empirical '
                     'intervention/testing study of corrections/retractions).\n'
                     '\n'
                     '- Title: "Efeito sinonímico entre fake news, '
                     'desinformação e liberdade de expressão: uma análise '
                     'materialista de discurso"\n'
                     '  - Author/date: Maraline Aparecida Soares — Date: '
                     '03/07/2024\n'
                     '  - Content: Thesis analyzing the discursive functioning '
                     'of fake news, disinformation and freedom of expression '
                     'from a materialist discourse analysis perspective. '
                     'Method: discourse analysis (not an empirical test of '
                     'corrective messages).\n'
                     '\n'
                     '- Title: "UM ESTUDO SEMÂNTICO ENUNCIATIVO DAS *HASTHAGS* '
                     'ELESIM NAS CAMPANHAS ELEITORAIS BRASILEIRAS DE 2018"\n'
                     '  - Author/date: Lucilene Justina da Silva — Date: '
                     '23/02/2024\n'
                     '  - Content: Semantic-enunciative analysis of #EleSim '
                     'hashtag use on Twitter in 2018 electoral campaigns; '
                     'corpus-based discourse analysis (not an empirical '
                     'correction-effectiveness study).\n'
                     '\n'
                     'Note: These entries include publication dates within '
                     '2021–2025 (or close) and concern misinformation, social '
                     'media, or hashtags, but none describe empirical '
                     'experimental or quasi-experimental tests of whether '
                     'corrections, retractions, or qualifiers change public '
                     'beliefs.',
                     'Extracted factual findings (2021–2025) from the source '
                     'relevant to persistence of misinformation and '
                     'explanations for why initial claims endure\n'
                     '\n'
                     'Key empirical findings on persistence and drivers of '
                     'enduring initial false claims\n'
                     '- False news spreads “significantly farther, faster, '
                     'deeper, and more broadly” than true news (Vosoughi et '
                     'al., 2018): analysis of ~126,000 Twitter cascades found '
                     'the disparity was driven by human behavior rather than '
                     'bots. False stories tended to be more novel and '
                     'emotionally evocative (e.g., surprise, disgust), '
                     'increasing share likelihood.\n'
                     '- Automated accounts (bots) play a disproportionate role '
                     'in early amplification: analysis of 14 million tweets '
                     'around the 2016 U.S. election found social bots '
                     'aggressively spread links from low‑credibility sources '
                     'in the crucial early moments to jumpstart viral momentum '
                     '(Shao et al., 2018).\n'
                     '- Demographic skew in sharing: Facebook activity during '
                     'the 2016 U.S. election showed a small fraction of users '
                     'accounted for the majority of fake‑news shares; '
                     'Americans over 65 shared several times more fake news '
                     'articles on average than younger groups (Guess et al., '
                     '2019).\n'
                     '- Systemic supply‑side failures (scientific '
                     'communication): interviews with scientists and health '
                     'communicators during COVID‑19 identified publication of '
                     'low‑quality or biased research, limited public access to '
                     'high‑quality findings, and insufficient public '
                     'understanding of science as drivers that seed and '
                     'sustain misinformation (Parker et al., 2021).\n'
                     '- Speed advantage of falsehoods vs. corrective '
                     'responses: viral false news spreads roughly 6× faster '
                     'than truth (benchmark). Fact‑check response time '
                     'improved from ~30–45 min (earlier) to ~15 min (by 2023), '
                     'but even a 15‑minute lag can be sufficient for false '
                     'narratives to embed and shape longer‑term beliefs.\n'
                     '- Cognitive/behavioral factors: many people do not '
                     'intend to spread misinformation but fail to consider '
                     'accuracy before sharing; prompting users to consider '
                     'accuracy significantly reduced sharing of false '
                     'headlines (Pennycook et al., 2021). Lack of attention to '
                     'accuracy at the moment of sharing helps misinformation '
                     'persist.\n'
                     '- Familiarity/repetition and “noise”: repeated exposure '
                     'increases perceived truthfulness (“familiarity effect”); '
                     'high‑volume bot activity can create information '
                     'overload, increasing chances that repeated falsehoods '
                     'stick.\n'
                     '- “Liar’s dividend”: the existence of fakes (deepfakes, '
                     'synthetic content) can allow bad actors to dismiss '
                     'authentic material as fake later, undermining trust and '
                     'making it easier for initial false claims or '
                     'counter‑claims to persist.\n'
                     '- Credibility conferred by synthetic identities and '
                     'coordinated networks: millions of AI‑generated personas '
                     'and coordinated botnets create the illusion of consensus '
                     'or grassroots support, lending apparent legitimacy to '
                     'initial false claims and making them harder to '
                     'dislodge.\n'
                     '- Microtargeting and personalization: AI‑enhanced '
                     'microtargeting increases persuasive impact of tailored '
                     'false messages; personalized misinformation is more '
                     'effective at persuading individuals than '
                     'one‑size‑fits‑all propaganda.\n'
                     '\n'
                     'Relevant quantitative benchmarks from 2019–2025 cited in '
                     'the text\n'
                     '- Global digital saturation (April 2025): 5.64 billion '
                     'active internet users (~68.7% of world population); 5.31 '
                     'billion social media accounts (~64.7% of world '
                     'population); average daily social media time 143–147 '
                     'minutes.\n'
                     '- Viral dynamics and detection benchmarks:\n'
                     '  - Viral false news spreads ~6× faster than truth.\n'
                     '  - Fact‑check latency improved from ~45 min to ~15 min '
                     '(2021→2023 benchmark).\n'
                     '  - Even 15 min is often sufficient to embed false '
                     'narratives.\n'
                     '- Deepfakes and synthetic media:\n'
                     '  - 550% growth in global deepfake videos (2019–2023); '
                     '95,820 deepfake videos in 2023.\n'
                     '  - Estimated ~500,000 deepfake videos shared on social '
                     'media by 2023; projections up to 8 million by 2025 '
                     '(reported projections vary).\n'
                     '  - Deepfake fraud attempts: +2,137% increase (period '
                     'referenced); deepfakes involved in 6.5% of fraud '
                     'incidents in 2023 (ACI Worldwide / Onfido figures '
                     'cited).\n'
                     '- AI‑generated text and sites:\n'
                     '  - AI‑generated fake‑news sites grew ~10× in one year; '
                     'NewsGuard counted 1,200+ such sites by 2024.\n'
                     '  - Some AI‑generated election disinformation fooled '
                     '>50% of human evaluators in one evaluation.\n'
                     '- Synthetic identities and bot scale:\n'
                     '  - 12.8 million+ fake personas reported used for '
                     'influence ops (summary figure).\n'
                     '  - $35 billion in synthetic ID fraud losses (2023, '
                     'Boston Fed cited).\n'
                     '  - Platforms report disabling 1.3 billion+ fake '
                     'accounts quarterly (Meta figure cited).\n'
                     '  - Bots estimated to drive ~25% of some platform '
                     'activity (e.g., Twitter in cited domains); bot traffic '
                     'comprised ~50% of total web traffic in 2023 with ~30–37% '
                     'from “bad bots” (Imperva/Statista/Akamai figures '
                     'cited).\n'
                     '- Microtargeting reach: AI‑enhanced propaganda estimated '
                     'to have reached ~34% of users in observed trends '
                     '(benchmark).\n'
                     '\n'
                     'Mechanisms summarized (why initial false claims endure)\n'
                     '- Novelty and emotion increase shareability, giving '
                     'false claims a head start.\n'
                     '- Early seeding/amplification by bots and synthetic '
                     'personas creates initial momentum and apparent '
                     'popularity.\n'
                     '- Rapid viral spread outpaces fact‑checking; short early '
                     'exposure can anchor beliefs.\n'
                     '- Repetition and high volume (bot-driven) increase '
                     'perceived validity via familiarity.\n'
                     '- Demographic and literacy gaps (e.g., older adults, '
                     'limited media science literacy) increase susceptibility '
                     'and secondary spread.\n'
                     '- Credibility gains from believable synthetic media '
                     '(deepfakes, AI‑written content) make false claims harder '
                     'to dislodge.\n'
                     '- Personalized microtargeting increases persuasive '
                     'effectiveness and reduces visibility of counter‑evidence '
                     'to targeted individuals.\n'
                     '- Systemic information‑supply failures (low‑quality '
                     'science communication, preprint hype, restricted access '
                     'to credible research) seed durable false narratives.\n'
                     '- Erosion of trust and the “liar’s dividend” mean even '
                     'accurate corrections may be doubted, allowing initial '
                     'falsehoods to persist.\n'
                     '\n'
                     'Interventions noted that reduce persistence (brief)\n'
                     '- Behavioral “accuracy prompts” (nudges) significantly '
                     'reduce sharing of false headlines (Pennycook et al., '
                     '2021).\n'
                     '- Faster detection/real‑time mitigation, '
                     'provenance/watermarking of AI content, and media '
                     'literacy/cognitive‑resilience campaigns are proposed '
                     'responses to limit initial spread and persistence.\n'
                     '\n'
                     '(End of extracted content relevant to persistence of '
                     'misinformation and explanations for why initial claims '
                     'endure.)',
                     'Title: Pariah or Partner? Reevaluating the U.S.-Saudi '
                     'Relationship\n'
                     '\n'
                     'Type: Policy Analysis (No. 961)\n'
                     '\n'
                     'Author: Jon Hoffman\n'
                     '\n'
                     'Date: September 20, 2023\n'
                     '\n'
                     'Summary (key recommendation from page): Instead of '
                     'deepening its entanglement in the region, the United '
                     'States should recognize the limited strategic importance '
                     'of the Middle East for American interests and begin '
                     'reevaluating the U.S.-Saudi relationship.',
                     'Extracted facts from the page relevant to post‑mortems / '
                     'case studies of media coverage and persistence of early '
                     'therapeutic claims (2021–2025):\n'
                     '\n'
                     'Definitions and diagnostic timelines\n'
                     '- National Academies of Science, Engineering, and '
                     'Medicine (NASEM, 2024) working definition of Long COVID '
                     '/ Post‑Acute COVID‑19 Syndrome (PACS): an '
                     'infection‑associated chronic condition present for at '
                     'least 3 months as a continuous, relapsing/remitting, or '
                     'progressive disease state affecting one or more organ '
                     'systems. The authors propose an analogous definition for '
                     'Post‑Acute COVID‑19 Vaccination Syndrome (PACVS) '
                     'requiring ≥3 months duration.\n'
                     '\n'
                     'Key numeric findings about persistence (relevant to '
                     'credibility of later claims)\n'
                     '- Soluble and extracellular‑vesicle (EV)–associated '
                     'spike protein detected up to 12 months in Long COVID '
                     'patients.\n'
                     '- S1 spike subunit detected in CD16+ monocytes up to 245 '
                     'days in SARS‑CoV‑2–negative individuals with '
                     'post‑vaccine syndrome.\n'
                     '- Short‑term mRNA vaccine reactogenicity commonly occurs '
                     'in the first 48–72 hours after mRNA vaccination.\n'
                     '- Commonly cited estimate range of PACVS disease burden: '
                     '0.2% to 0.9% of COVID‑19 vaccine recipients developing '
                     'the condition.\n'
                     '\n'
                     'Evidence of information suppression, institutional '
                     'response, and media/policy effects\n'
                     '- Official messaging during the pandemic typically '
                     'minimized vaccine risks.\n'
                     '- The authors state the Biden administration pressured '
                     'social media companies to remove content it defined as '
                     '“vaccine misinformation”; the authors assert this '
                     'removed a mix of genuine misinformation, disputed '
                     'statements, scientifically supported statements, and '
                     'patient experiences.\n'
                     '- Restrictions on online speech are described as likely '
                     'contributing to a suboptimal COVID‑19 response and to '
                     'marginalization of PACVS patients.\n'
                     '- Social media companies were reportedly pressured to '
                     'remove support groups for post‑vaccination '
                     'complications; the article states some removed content '
                     'constituted factual personal testimony.\n'
                     '- The authors state that constant messaging about '
                     '“vaccine misinformation” may have made doctors less '
                     'receptive to PACVS patients’ accounts.\n'
                     '\n'
                     'Barriers to reporting, causality assessment, and '
                     'research follow‑up\n'
                     '- Clinicians: some physicians reportedly were dissuaded '
                     'from submitting reports to the Vaccine Adverse Event '
                     'Reporting System (VAERS).\n'
                     '- VAERS is described as a passive surveillance program '
                     'that is underreported, often incompletely filled, and '
                     'lacking verification procedures; VAERS reports do not '
                     'prove causality and are initial signals requiring formal '
                     'epidemiological review.\n'
                     '- Fraudulent VAERS reports are described as rare and '
                     'usually removed, representing a negligible proportion of '
                     'total reports.\n'
                     '- WHO causality assessment algorithm for vaccine adverse '
                     'events has been critiqued as potentially disqualifying '
                     'causal relationships when alternative explanations '
                     'exist.\n'
                     '- The temporal assumption that vaccine adverse effects '
                     'would be restricted to the 2‑week period after '
                     'immunization is challenged by evidence of longer '
                     'persistence of spike antigen or mRNA in some cases.\n'
                     '- The vaccine‑injured have reportedly had difficulty '
                     'accessing compensation for trial injuries and in some '
                     'cases have had to fund their own research.\n'
                     '\n'
                     'Consequences and recommendations (as related to '
                     'recognition, public messaging, research)\n'
                     '- Delayed recognition and marginalization of PACVS '
                     'patients is described as having created barriers to care '
                     'and deprioritized research.\n'
                     '- The authors recommend formally recognizing PACVS '
                     '(including adding a diagnostic code to ICD‑10/ICD‑11), '
                     'biobanking linked to clinical trajectories, '
                     'identification of susceptibility factors, and funding '
                     'for clinical trials and therapeutic research.\n'
                     '- They emphasize listening to patient experience to '
                     'restore trust.\n'
                     '\n'
                     'Mechanistic/policy details that intersect with '
                     'credibility of persistent claims\n'
                     '- Evidence cited in the article that spike (and S1) can '
                     'persist and have biological effects is presented as a '
                     'mechanistic basis that could make longer‑term adverse '
                     'effects biologically plausible—this mechanistic '
                     'plausibility is cited in the article as relevant to '
                     'assessing causality and interpreting reports that were '
                     'sometimes suppressed or dismissed.\n'
                     '\n'
                     'Note: The above items are direct factual statements and '
                     'numeric data reported in the article that are relevant '
                     'to how media coverage, institutional messaging, '
                     'censorship, and reporting systems influenced '
                     'persistence, recognition, and public perception of early '
                     'claims about post‑vaccine/post‑infection sequelae.',
                     'Summary of findings (relevant to 2021–2025 analyses of '
                     'social media amplification and algorithmic reinforcement '
                     'of initial news frames)\n'
                     '\n'
                     'Overview\n'
                     '- The review included 78 empirical studies (search '
                     'window 2015–2025; final corpus = 78). A thematic '
                     'synthesis identified a cluster of 26 studies addressing '
                     'algorithmic amplification of polarization, '
                     'misinformation, and self-censorship (Theme 4).\n'
                     '- Inter-rater reliability for screening and appraisal: '
                     'Cohen’s κ = 0.82.\n'
                     '- Core claim: algorithmic recommendation and visibility '
                     'logics optimized for engagement/virality reframe '
                     'newsworthiness toward “shareworthiness,” amplifying '
                     'polarizing and misinformative content and influencing '
                     'newsroom behavior and framing.\n'
                     '\n'
                     'Empirical patterns (2021–2025 studies and findings)\n'
                     '- Algorithmic amplification of polarization\n'
                     '  - Multiple recent studies document that '
                     'personalization and ranking systems produce '
                     'echo-bubble/filter-bubble effects that deepen '
                     'ideological clustering and reinforce partisan frames.\n'
                     '  - Examples from 2024–2025:\n'
                     '    - Chiridza & Mare (2025): news-feed personalization '
                     'produces “echo-bubble” effects, amplifying polarization '
                     'and misinformation.\n'
                     '    - Zhao & Ye (2025): content-matching mechanisms '
                     'align news visibility with users’ political '
                     'predispositions, deepening divides in regional '
                     'contexts.\n'
                     '    - Comparative analysis (Fang & Cheng, 2022) shows '
                     'Facebook’s curation tendencies favor ideological '
                     'clustering even on diversified platforms.\n'
                     '\n'
                     '- Algorithmic role in misinformation propagation\n'
                     '  - Algorithms privileging novelty, emotion, and '
                     'engagement contribute to rapid diffusion and persistence '
                     'of misinformative content.\n'
                     '  - Notable findings:\n'
                     '    - He et al. (2021): on YouTube, algorithmic '
                     'recommendation loops sustain cycles of misinformative '
                     'political content.\n'
                     '    - Moyo et al. (2019) and Kafiliveyjuyeh et al. '
                     '(2025): algorithmic systems tend to prioritize '
                     'novelty/emotionality over accuracy, degrading '
                     'credibility signals.\n'
                     '    - Fleerackers et al. (2025): factors driving '
                     'republication and Facebook amplification differ from '
                     'other amplification dynamics, indicating '
                     'platform-specific misinformation pathways.\n'
                     '\n'
                     '- Algorithmically induced changes to newsroom framing '
                     'and self-censorship\n'
                     '  - Visibility economies and engagement metrics reshape '
                     'editorial timetables, topic selection, and framing '
                     'choices; this includes anticipatory editorial restraint '
                     'to avoid low-engagement topics or backlash.\n'
                     '  - Evidence from 2021–2024:\n'
                     '    - Appelgren (2023): newsroom producers adapt '
                     'editorial timetables to engagement imperatives, avoiding '
                     'low-visibility topics.\n'
                     '    - He et al. (2021): fear of follower backlash on '
                     'Twitter contributes to anticipatory self-editing by '
                     'journalists.\n'
                     '    - García-Perdomo (2024): Colombian TV newsrooms '
                     'adjust formats and coverage to Facebook distribution '
                     'metrics.\n'
                     '    - Tandoc & Maitra (2018) (earlier example referenced '
                     'in synthesis): rumor proliferation shaped newsroom risk '
                     'calculations in the Philippines (used to illustrate '
                     'similar dynamics).\n'
                     '\n'
                     'Validated mechanisms (synthesized across Theme 4)\n'
                     '1. Optimization for divisiveness: algorithms '
                     'systematically privilege content that maximizes '
                     'engagement, leading to increased polarization.\n'
                     '2. Lowering epistemic thresholds: recommendation loops '
                     'and viral reposting amplify misinformation by '
                     'privileging signals other than accuracy.\n'
                     '3. Restructuring newsroom practices: metric-driven '
                     'visibility logics induce self-censorship and reframe '
                     'editorial priorities toward content expected to perform '
                     'under algorithmic logics.\n'
                     '\n'
                     'Corpus heterogeneity and contingency\n'
                     '- The review emphasizes that algorithmic effects are '
                     'contingent and platform-specific: amplification and '
                     'reinforcement of frames vary across platforms and '
                     'regions.\n'
                     '- Theme 4’s coding included a “Mitigating Factors” '
                     'dimension identifying cases where platform effects were '
                     'uneven or moderated by local/contextual conditions.\n'
                     '\n'
                     'Implications and recommended research priorities (from '
                     'Theme 4)\n'
                     '- Research: need for longitudinal, cross-regional '
                     'recommender-system audits and mixed-method studies '
                     'combining algorithmic audits, log data, and newsroom '
                     'ethnography to capture temporal dynamics and editorial '
                     'adaptation.\n'
                     '- Governance: prioritize platform accountability, '
                     'algorithmic transparency, and routine '
                     'exposure/visibility audits to detect adverse selection '
                     'toward sensationalism or identity-driven visibility.\n'
                     '- Practice: design and audit recommender systems and '
                     'metric portfolios to reduce incentives for divisive '
                     'framing and to elevate accuracy and civic value '
                     'alongside engagement.',
                     '- Author conducted an undergraduate content analysis of '
                     'The Daily Telegraph comparing coverage of the Syrian '
                     'refugee crisis (early stages, 2011) with reporting on '
                     'the Ukrainian refugee crisis (2022).\n'
                     '  - Method: framing theory; analysed five common media '
                     'frames: human interest, morality, economic consequences, '
                     'responsibility and conflict.\n'
                     '  - Findings:\n'
                     '    - Syrian refugees (2011 coverage) were predominantly '
                     'portrayed through economic and conflict frames; articles '
                     'emphasized burden on UK/EU economies, tensions/security '
                     'risks at borders, and framed Syrians as a faceless '
                     '“migrant wave.” Personal stories were rare.\n'
                     '    - Ukrainian refugees (2022 coverage) were dominated '
                     'by human-interest and moral framing; reporting centered '
                     'personal narratives (families, mothers with children, '
                     'fathers staying to fight), quoted political leaders '
                     'calling for compassion, and used headlines conveying '
                     'urgency and outrage.\n'
                     '\n'
                     '- Examples of sourcing and language that illustrate '
                     'framing and headline bias:\n'
                     '  - NBC reporter Kelly Cobiella (2022): “not refugees '
                     'from Syria ... they’re Christians, they’re white, they '
                     'look like us.”\n'
                     '  - CBS correspondent Charlie D’Agata (2022): described '
                     'Ukraine as a “relatively civilized” place.\n'
                     '  - BBC headline after the Bondi Beach mass shooting '
                     '(Dec 2025): “Bondi Beach gunman originally from India, '
                     'police say.” (Pointed out as an instance of '
                     'foregrounding origin.)\n'
                     '  - BBC framing after the Christchurch mosque shootings '
                     '(March 2019): largely framed the perpetrator as an '
                     '“individual extremist” (contrast cited with other '
                     'coverage).\n'
                     '\n'
                     '- Examples of linguistic framing choices affecting '
                     'perceived responsibility and urgency:\n'
                     '  - Coverage of Gaza: Palestinians often described as '
                     '“dying” rather than “being killed”; responsibility '
                     'softened by terms such as “clashes” or “crossfire.” '
                     'Starvation frequently framed as a humanitarian concern '
                     'rather than the result of deliberate policy.\n'
                     '  - Headline and early reporting choices (e.g., '
                     'emphasizing an attacker’s origin) are highlighted as '
                     'shaping instinctive reactions before facts have time to '
                     'settle.\n'
                     '\n'
                     '- Other relevant factual claims about media attention '
                     'and scale of crises:\n'
                     '  - Sudan: described as one of the world’s worst '
                     'humanitarian catastrophes; “tens of thousands have been '
                     'killed, millions displaced and millions more pushed '
                     'toward famine.” (Noted as receiving little sustained '
                     'Western media attention.)\n'
                     '\n'
                     '- Implication emphasized in the article: editorial '
                     'choices about which stories to prioritize, which voices '
                     'to amplify, sourcing and early headline framing '
                     'materially shape public perception, moral urgency, and '
                     'policy responses.',
                     'Scope and aim\n'
                     '- Exploratory analysis of how academic studies frame '
                     'media coverage of the Israeli–Palestinian conflict, '
                     'examining biases and why initial framings persist. Data '
                     'sources: SAGE, JSTOR, and IJAES. Final sample: 35 '
                     'research papers (selected from an initial ~98 publicly '
                     'available journals). Timeframe of included publications '
                     'filtered to 2000–2024.\n'
                     '\n'
                     'Theoretical frameworks and interdisciplinary lenses used '
                     'to explain persistence of initial framings\n'
                     '- Framing theory: Druckman’s Framing Effects (2001) and '
                     'Levin, Schneider, & Gaeth (1998) — distinction between '
                     'equivalency framing (risky choice, attribute, goal '
                     'framing) and emphasis/issue framing '
                     '(selecting/emphasizing subsets of considerations).\n'
                     '- Cognitive Critical Discourse Analysis (CDA): used to '
                     'reveal language choices and underlying '
                     'cognitive/ideological frames that shape interpretation '
                     'and maintain frames over time.\n'
                     '- Fairclough’s intertextuality (1992): '
                     'recontextualization of texts and linkage to wider '
                     'discourses, explaining how frames are reinforced across '
                     'scholarship and media.\n'
                     '- Visual framing: strategic use of images and '
                     'infographics (e.g., by state actors) to shape '
                     'sympathy/legitimacy—visual content operates as a durable '
                     'frame in public perception.\n'
                     '- Argument that academics are influenced by media '
                     'narratives and their own ideological communities; '
                     'self-selection of research topics and intergroup '
                     'ideologies contributes to reproduction and persistence '
                     'of initial frames.\n'
                     '\n'
                     'Methodology relevant to persistence explanations\n'
                     '- Mixed qualitative/computer-assisted text analysis: '
                     'NVivo used for corpus analysis, word frequency and '
                     'word-tree mapping to identify dominant lexical frames '
                     'and co-occurrence patterns.\n'
                     '- Purposive sampling of journal articles relevant to the '
                     'Israeli–Palestinian conflict from JSTOR, SAGE, and '
                     'region-based IJAES.\n'
                     '- Analytical combination: corpus/lexical patterns '
                     '(NVivo) + Framing Effects model + intertextual analysis '
                     'to link textual patterns to ideological sources and '
                     'cognitive framing processes.\n'
                     '\n'
                     'Key empirical findings explaining why initial framings '
                     'persist (media, cognitive, and policy mechanisms)\n'
                     '- Three recurrent framing strategies found across the '
                     'sampled academic articles:\n'
                     '  1. Actors’ agency framing — portraying one side as '
                     'active agent and the other as passive object (e.g., '
                     'Israel as active implementer of policy; Palestinians as '
                     'object/victims). This assigns causal roles and '
                     'stabilizes perceptions of responsibility.\n'
                     '  2. Attack/self-defense narrative — framing responses '
                     'as retaliatory or defensive normalizes and locks in '
                     'moral interpretations (legitimacy of actions vs. '
                     'humanitarian crisis).\n'
                     '  3. Framing of Hamas and international actors — '
                     'labeling and image strategies (e.g., scripting Hamas as '
                     '“terroristic perpetrators” or emphasizing international '
                     'military/political support) consolidate threat/ally '
                     'frames.\n'
                     '- Cognitive mechanism: equivalency and emphasis framing '
                     'change preferences and moral attributions depending on '
                     'wording and which aspects are emphasized; such framing '
                     'effects are durable when reinforced across media and '
                     'academic discourse.\n'
                     '- Intertextual mechanism: academic texts draw on and '
                     're-use historical narratives (e.g., Nakba, Holocaust, '
                     'exile/return) and policy/legal repertoires; these '
                     'intertextual links recontextualize current events within '
                     'existing frames, perpetuating them.\n'
                     '- Source/author effects (policy and institutional '
                     'mechanism): authors’ cultural, political, and '
                     'institutional backgrounds systematically shape their '
                     'framing choices; academic affiliation and '
                     'disciplinary/community norms act as channels that '
                     'reproduce and reinforce particular frames.\n'
                     '- Visual/media strategy mechanism: state and '
                     'institutional actors’ strategic use of images and '
                     'messaging serves to legitimize particular framings '
                     '(e.g., victimhood, security) and reinforces those frames '
                     'in both media and scholarly commentary.\n'
                     '\n'
                     'Quantitative/lexical evidence (indicative of persistent '
                     'lexical framing)\n'
                     '- Lexical counts (top occurrences across platforms — '
                     'SAGE / JSTOR / IJAES):\n'
                     '  - “Palestine/Palestinian/Palestinians”: 1072 / 2361 / '
                     '833\n'
                     '  - “Israel/Israeli”: 1626 / 1428 / 326\n'
                     '  - “Gaza”: 619 / 195 / 101\n'
                     '  - “Politics”: 358 / 360 / n/a\n'
                     '  - “Hamas”: 181 / 177 / n/a\n'
                     '  - “War”: 527 / 209 / n/a\n'
                     '  - “Conflict”: 463 / 266 / n/a\n'
                     '  - “Land”: 242 / n/a / 84\n'
                     '  - “Arab(s)”: n/a / 716 / 74\n'
                     '  - “Zionist”: n/a / 131 / 93\n'
                     '  - “International”: n/a / 168 / 89\n'
                     '- Example corpus metric: SAGE dataset contained 380 '
                     'occurrences of the term “framing” (used as indicative of '
                     'academic emphasis on media framing).\n'
                     '\n'
                     'Hypotheses tested and outcomes relevant to persistence\n'
                     '- Hypothesis I: Academic studies frame media’s role '
                     'aligned with authors’ ideological perspectives — '
                     'strongly supported. Academics critique selective media '
                     'amplification (e.g., “security,” “terrorism”) that '
                     'reinforces state-centric narratives.\n'
                     '- Hypothesis II: Patterns of representation vary by '
                     'author cultural/political/institutional background — '
                     'supported. Middle Eastern and Palestinian-linked '
                     'scholars emphasize historical grievances (Nakba, '
                     'displacement); Israeli/Western-affiliated scholars '
                     'emphasize security, sovereignty, legality.\n'
                     '- Hypothesis III: Academic framing contributes to '
                     'perpetuating or mitigating broader conflict dynamics — '
                     'supported with nuance. Framing often perpetuates '
                     'polarization (in-group/out-group distinctions) but '
                     'academic scholarship also offers alternative frames '
                     '(dialogue, shared-sovereignty proposals) that could '
                     'mitigate dynamics if adopted.\n'
                     '\n'
                     'Conclusions relevant to why initial framings persist '
                     '(media, cognitive, policy explanations)\n'
                     '- Media-level: selective emphasis and imagery by media '
                     'and state actors create durable public frames which are '
                     'amplified and legitimized when taken up by academics.\n'
                     '- Cognitive-level: framing effects (equivalency and '
                     'emphasis) alter perceptions and moral judgments; '
                     'combined with repeated exposure and intertextual '
                     'reinforcement, these effects persist.\n'
                     '- Policy/institutional-level: authors’ institutional '
                     'affiliations, national/political contexts, and the '
                     'strategic actions of states and international actors '
                     '(military/political support narratives, legal framings) '
                     'institutionalize particular frames in both public and '
                     'scholarly discourse.\n'
                     '- Result: a feedback loop exists—media frames influence '
                     'academics; academic framing re-legitimizes and '
                     'disseminates frames back to policy and public '
                     'arenas—explaining persistence of initial framings and '
                     'their influence on policy and conflict dynamics.',
                     'Extracted facts relevant to the subtask ("2021–2025 '
                     'studies on the role of political elites and advocacy '
                     'groups in sustaining initial narratives despite later '
                     'evidence") from the page:\n'
                     '\n'
                     'Study metadata\n'
                     '- Article: Moorcroft H, Hampton S, Whitmarsh L (2025). '
                     'Received: 2 Aug 2024; Accepted: 7 Jan 2025; Published: 5 '
                     'Mar 2025.\n'
                     '- Sample: survey N = 1,036 (verified responses N = 1,001 '
                     'after QC); wealthy sub-sample n = 43 (<10% of total); 16 '
                     'wealthy interviewees (semi-structured).\n'
                     '\n'
                     'Contextual findings about wealthy people, influence, and '
                     'advocacy\n'
                     '- Wealthy people possess the capacity to exert influence '
                     'in social and professional networks but show low '
                     'motivation to reduce consumption.\n'
                     '- Wealthy people act as role models and can define and '
                     'demonstrate “the good life” through carbon‑intensive '
                     'goods and activities (e.g., exotic holidays, expensive '
                     'cars).\n'
                     '- The article cites Oxfam’s 2020 report “Confronting '
                     'Carbon Inequality” as having driven media coverage about '
                     'affluent consumption and emissions inequality; it states '
                     'NGOs (e.g., Oxfam) have tried to raise awareness of '
                     'emissions inequality but argues these messages need '
                     'amplification.\n'
                     '- The authors state: “Shifting the narrative from one of '
                     'blame to one of opportunity may be more constructive '
                     'than inducing guilt and running the risk that wealthy '
                     'people use their influence for climate delay.”\n'
                     '- The authors argue researchers, climate activists and '
                     'other non-governmental advocates “have a key role to '
                     'play in highlighting emissions inequalities and '
                     'generating pressure on wealthy people to shoulder '
                     'responsibility.”\n'
                     '\n'
                     'Quantitative findings on influence and communication '
                     '(selected statistics)\n'
                     '- Wealthy participants were significantly more likely to '
                     'report they could influence decisions in their local '
                     'area: wealthy mean = 4.00 (SD = 1.14) vs non-wealthy '
                     'mean = 2.84 (SD = 1.48); t(999) = 3.20, p = .001.\n'
                     '- Wealthy participants were significantly more likely to '
                     'report they could influence those around them to reduce '
                     'their climate impact: wealthy mean = 6.30 (SD = 3.96) vs '
                     'non-wealthy mean = 4.05 (SD = 3.30); t(1034) = 4.34, p < '
                     '.001.\n'
                     '- Wealthy participants were significantly more likely to '
                     'have had a conversation about climate change in the past '
                     'month: χ2(1, N = 1036) = 10.9, p < .001, φ = .102. '
                     'Regression analysis identified income as the most '
                     'significant predictor of increased discussion when '
                     'controlling for demographic variables.\n'
                     '- Wealthy participants were significantly more likely to '
                     'agree that attempting to influence managers and leaders '
                     'at work is effective: wealthy mean = 4.74 (SD = 1.63) vs '
                     'non-wealthy mean = 4.10 (SD = 1.43); t(1034) = 2.88, p = '
                     '.004 (non-significant when controlling for other '
                     'demographics).\n'
                     '- Wealthy participants were significantly more likely to '
                     'report they are in the process of or have already acted '
                     'to influence those at work: χ2(1, N = 1035) = 43.0, p < '
                     '.001, φ = .204. Income remained a significant predictor '
                     'of utilised workplace influence (alongside education) '
                     'when controlling for other demographics.\n'
                     '\n'
                     'Findings on how influence is used (constraints and '
                     'effects)\n'
                     '- Although wealthy people report higher climate literacy '
                     'and discuss climate change more, they often do not use '
                     'influence in non-workplace contexts to reduce emissions '
                     'and may instead normalize high‑carbon practices in their '
                     'networks.\n'
                     '- Interview evidence indicates wealthy participants '
                     'sometimes feel under‑educated to be persuasive: “I don’t '
                     'have at my command the level of detailed and factual '
                     'evidence that I would need to be persuasive” (P8).\n'
                     '- Wealthy participants were significantly more likely to '
                     'agree that people close to them fly regularly for '
                     'leisure: wealthy mean = 4.91 (SD = 1.97) vs non-wealthy '
                     'mean = 3.57 (SD = 1.86); t(1034) = 4.59, p < .001.\n'
                     '- Wealthy participants were significantly more likely to '
                     'agree that those around them would disapprove if they '
                     'stopped flying: wealthy mean = 3.51 (SD = 2.12) vs '
                     'non-wealthy mean = 2.69 (SD = 1.63); t(44.2) = 2.51, p = '
                     '.016.\n'
                     '- The study notes wealthy people’s influence can both '
                     'normalise excessive consumption and, alternatively, '
                     'support uptake of low‑carbon technologies (e.g., rooftop '
                     'solar peer effects).\n'
                     '\n'
                     'Policy and political messaging points\n'
                     '- The authors note “increasingly mixed messages from the '
                     'UK Government,” citing an example policy shift: the '
                     'delayed deadline for the phase‑out of new petrol and '
                     'diesel vehicle sales (from 2030 to 2035).\n'
                     '- The paper recommends protecting climate policy from '
                     'political cycles and amplifying advocacy messaging to '
                     'increase pressure on wealthy people to use their '
                     'influence for emissions reduction.\n'
                     '- The authors note public support context: “a majority '
                     'of people in the UK express support for a frequent flyer '
                     'levy” (no numerical percent reported in the article '
                     'text).\n'
                     '\n'
                     'Other relevant numeric/contextual details\n'
                     '- Global and UK inequality context cited: “the richest '
                     '10% of the population account for over half of global '
                     'emissions from 1990–2015” (cited); in the UK, household '
                     'emissions of the wealthiest 10% are reported as three '
                     'times that of the poorest 10%.\n'
                     '- Wealthy sample behaviors relevant to '
                     'influence/narrative: 7% of the wealthy sample report '
                     'flying more than 40 hours in the past year.\n'
                     '- Adoption/investment relevant to influence: wealthy '
                     'respondents were significantly more likely to be in '
                     'process of or have purchased a heat pump: χ2(1, N = '
                     '1036) = 12.0, p < .001, φ = .107; and an electric '
                     'vehicle: χ2(1, N = 1036) = 63.6, p < .001, φ = .248.\n'
                     '\n'
                     'Direct quotes on advocacy/influence and narratives '
                     '(selected)\n'
                     '- “If you invest £10,000 in solar panels, and it goes '
                     'wrong? Well, it’s only ten‑thousand pounds” (P7) — on '
                     'financial insulation enabling green investment.\n'
                     '- “I don’t mind how many regulations there are, I will '
                     'completely go along with all of them… I’d rather that '
                     'than have it all left up to individual choice…” (P3) — '
                     'on preference for regulatory policy.\n'
                     '- “Shifting the narrative from one of blame to one of '
                     'opportunity may be more constructive than inducing guilt '
                     'and running the risk that wealthy people use their '
                     'influence for climate delay.” (authors’ discussion)\n'
                     '- “Researchers, climate activists and other '
                     'non‑governmental advocates have a key role to play in '
                     'highlighting emissions inequalities and generating '
                     'pressure on wealthy people to shoulder responsibility '
                     'for their disproportionate contribution to global '
                     'climate change.” (authors’ conclusion)\n'
                     '\n'
                     'Notes on study limitations (relevant to interpreting '
                     'influence findings)\n'
                     '- Wealthy sub-sample small: n = 43; authors state this '
                     'is large for studies of wealthy people but acknowledge '
                     'limitations.\n'
                     '- Interviews were only conducted with wealthy people (no '
                     'qualitative comparison group).',
                     'No relevant content found',
                     'Title and scope\n'
                     '- Understanding COVID-19 Media Framing: Comparative '
                     'Insights from Germany, the US, and the UK During Omicron '
                     '(reporting period: 1 December 2021 – 31 March 2022).\n'
                     '- Study compares issue-specific media frames in three '
                     'left‑liberal national dailies: Süddeutsche Zeitung (SZ, '
                     'Germany), The New York Times (NYT, US), The Guardian '
                     '(UK).\n'
                     '\n'
                     'Data and methods (relevant factual details)\n'
                     '- Article collection: search term “COVID-19 OR Corona” '
                     '(excluding regional, arts/culture, sports); sources: '
                     'LexisNexis and archives.\n'
                     '- Sampling: artificial-week procedure from 10,937 '
                     'articles to a sample of 5,116; after data cleaning, '
                     '1,878 articles were manually coded (SZ: 908; NYT: 515; '
                     'Guardian: 377).\n'
                     '- Coding system: 115 dichotomous variables derived from '
                     'Entman’s frame elements; only variables with ≥5% '
                     'prevalence per newspaper included in cluster analysis.\n'
                     '- Inter-coder reliability (Krippendorff’s alpha): '
                     '0.703.\n'
                     '- Frame identification: hierarchical cluster analysis '
                     '(Ward method); four-cluster solutions chosen for each '
                     'newspaper.\n'
                     '\n'
                     'Prevalence of opinionated vs neutral presentation '
                     '(percent)\n'
                     '- Süddeutsche Zeitung (SZ): 16.0% opinionated articles.\n'
                     '- The New York Times (NYT): 3.7% opinionated articles '
                     '(97.0% neutral).\n'
                     '- The Guardian: 2.1% opinionated articles.\n'
                     '\n'
                     'Identified frames and their prevalence by newspaper '
                     '(percent of that paper’s articles)\n'
                     '- Süddeutsche Zeitung (SZ) — four frames:\n'
                     '  - Economic impact frame: 42.4%\n'
                     '  - Omicron impact frame: 28.5%\n'
                     '  - Vaccination strategy/problems frame: 19.1%\n'
                     '  - Social division frame: 10.0%\n'
                     '  - Temporal notes: Omicron and vaccination frames each '
                     '~20% per month Dec–Feb; vaccination frame declines while '
                     'Omicron increases in March; economic frame ~40% monthly; '
                     'social division highlighted mainly in December then '
                     'declines.\n'
                     '\n'
                     '- The New York Times (NYT) — four frames:\n'
                     '  - Omicron/mutation impact frame: 48.2%\n'
                     '  - Economic & vaccination issues combined frame: 27.2%\n'
                     '  - Social division frame: 16.5%\n'
                     '  - Test strategy frame: 8.2%\n'
                     '  - Temporal notes: Omicron frame ~45% monthly; '
                     'economic+vaccination frame peaks ~February–March (~40%); '
                     'social division ~17% steady; test frame peaks in January '
                     'then declines.\n'
                     '\n'
                     '- The Guardian — four frames:\n'
                     '  - Economic, financial, and social impact frame: 34.0%\n'
                     '  - Omicron impact frame: 33.7%\n'
                     '  - Vaccination strategy/problems frame: 21.2%\n'
                     '  - Impact on healthcare sector frame: 11.1%\n'
                     '  - Temporal notes: economic/social frame rises to peak '
                     '70.5% in February; Omicron frame high in December (45%) '
                     'and March (37%); vaccination frame ~23% average then '
                     'declines in March; healthcare-sector frame ~19.2% in '
                     'December then decreases.\n'
                     '\n'
                     'Cross‑country comparative findings (relevant factual '
                     'points)\n'
                     '- Dominant frame across all three newspapers: Omicron '
                     'impact (single largest frame for NYT; among top frames '
                     'for SZ and Guardian).\n'
                     '- Relative emphases:\n'
                     '  - SZ emphasizes economic impact most strongly '
                     '(42.4%).\n'
                     '  - NYT emphasizes Omicron impact most strongly (48.2%) '
                     'and treats testing as a distinct frame (only paper with '
                     'notable testing frame).\n'
                     '  - Guardian gives roughly equal weight to '
                     'economic/social consequences and Omicron (34.0% and '
                     '33.7%).\n'
                     '- Blame and negative evaluations: present across all '
                     'papers and frames; Guardian shows the highest prevalence '
                     'of emotionally charged evaluations and accusations '
                     '(often directed at unvaccinated people and politics). SZ '
                     'and NYT also allocate blame across frames (SZ: moderate '
                     'blame on politics and on population in some frames; NYT: '
                     'blame assigned to both politics and population across '
                     'frames).\n'
                     '- Tone differences: SZ and Guardian described as having '
                     'emotionally charged reporting in some frames; NYT '
                     'described as more objective/informative except where '
                     'addressing social impacts.\n'
                     '\n'
                     'Other methodological constraints noted in the article '
                     '(relevant to interpreting prevalence/reach)\n'
                     '- Variables with prevalence <5% per newspaper were '
                     'excluded from cluster analysis (i.e., frames/variables '
                     'below that threshold were not analyzed in clustering).\n'
                     '- Study timeframe focuses on Dec 2021–Mar 2022 (Omicron '
                     'hot phase); results reflect that period and the three '
                     'selected left‑liberal newspapers only. Data '
                     'availability: coded data available from corresponding '
                     'author on request.',
                     'Summary of relevant content for subtask "2021–2025 '
                     'post‑publication reviews or investigations specifically '
                     'addressing the hydroxychloroquine controversy and why '
                     'early framings persisted":\n'
                     '\n'
                     '- No content on this page pertains to '
                     'hydroxychloroquine, post-publication reviews, or '
                     'investigations from 2021–2025.\n'
                     '- The page is a blog post about polyandry (Draupadi) and '
                     'contains extensive unrelated comments and spam; there '
                     'are no sections, numeric data, or references relevant to '
                     'the hydroxychloroquine controversy.',
                     'No relevant content found']],
 'failed_steps': [],
 'final_report': 'Answer (direct):  \n'
                 'Major claim (2020–2022) — “Hydroxychloroquine (HCQ) is an '
                 'effective treatment for COVID‑19.” This claim was widely '
                 'repeated in early 2020 as an asserted potential therapy (and '
                 'was temporarily supported by an FDA Emergency Use '
                 'Authorization). Later evidence (2020 revocation plus '
                 '2023–2025 trials, systematic reviews, and guidance) '
                 'substantially weakened and reframed that claim: randomized '
                 'trials and meta‑analyses show no demonstrated clinical '
                 'benefit in hospitalized patients or for pre‑exposure '
                 'prophylaxis, and they show increased adverse events (notably '
                 'QTc prolongation), leading to formal revocation of the EUA '
                 'and explicit advisories against routine use. Nonetheless, '
                 'the earlier efficacy framing persists in media and some '
                 'public discourse. Below I summarize the evidence, show how '
                 'wording shifted over time, and summarize documented '
                 'mechanisms that help explain persistence. I list '
                 'uncertainties and key missing data at the end.\n'
                 '\n'
                 '1) Primary 2020–2022 statements asserting or '
                 'institutionalizing the original claim (exact phrasing from '
                 'the evidence)\n'
                 '- FDA Emergency Use Authorization (EUA), March 28, 2020 (FDA '
                 '/ BARDA authorization metadata reported in the evidence): '
                 'the EUA authorized “hydroxychloroquine sulfate and '
                 'chloroquine phosphate donated to the Strategic National '
                 'Stockpile (SNS)” “to be distributed from the SNS to states '
                 'and used for certain hospitalized patients with COVID‑19 — '
                 'specifically for adolescent and adult patients hospitalized '
                 'with COVID‑19, as appropriate, when a clinical trial is not '
                 'available or feasible.” (March 28, 2020 EUA summary in the '
                 'evidence.)\n'
                 '- Contemporary guidance communications (state-level notice '
                 'cited): FDA guidance or communications to prescribers '
                 'described the EUA as “authorizing emergency use of '
                 'chloroquine phosphate and hydroxychloroquine sulfate … for '
                 'the treatment of COVID‑19.” (Michigan LARA communication '
                 'summarized in the evidence.)\n'
                 '\n'
                 '2) Early reversal by regulators (exact phrasing from the '
                 'evidence)\n'
                 '- FDA revocation notice, June 15, 2020 (Federal Register '
                 'reprint summarized in the evidence): FDA revoked the EUA and '
                 'stated that “based on ongoing analysis and emerging '
                 'scientific data, chloroquine and hydroxychloroquine are '
                 'unlikely to be effective in treating COVID‑19 for the '
                 'authorized uses,” and that “ongoing serious cardiac adverse '
                 'events and other potential serious side effects mean the '
                 'known and potential benefits no longer outweigh the known '
                 'and potential risks.” The Federal Register reprint '
                 'reiterates: FDA “concluded it is no longer reasonable to '
                 'believe oral chloroquine phosphate and hydroxychloroquine '
                 'sulfate may be effective” and therefore revoked the EUA '
                 '(revocation effective June 15, 2020).\n'
                 '\n'
                 '3) 2023–2025 evidence that weakens/reframes the original '
                 'claim (exact phrasings and key findings from the supplied '
                 'sources)\n'
                 '- Systematic review / meta‑analysis of HCQ/CQ in '
                 'hospitalized patients (search Dec 10, 2022–Feb 15, 2024; 9 '
                 'studies included): key phrasing in the review: “The '
                 'available RCTs and retrospective studies did not demonstrate '
                 'therapeutic benefit of HCQ (or CQ at tested regimens) for '
                 'hospitalized COVID‑19 patients.” Numeric and safety findings '
                 'in the review: QTc prolongation occurred variably (reported '
                 'ranges across studies: 12%–93% of patients); one trial '
                 'reported mean CQ QTc prolongation 35 ms (95% CI 28–43 ms); '
                 'high‑dose chloroquine increased risk of QTc > 500 ms and was '
                 '“not recommended for critically ill patients.” Review '
                 'conclusion recommended “continuous ECG surveillance and '
                 'individualized risk assessment” when these drugs are used. '
                 '(Extracted from the provided systematic review summary.)\n'
                 '- Meta‑analysis of HCQ as pre‑exposure prophylaxis in '
                 'healthcare workers (search through March 14, 2023; 10 RCTs, '
                 'N = 5,079): key phrasing: “HCQ, compared with placebo, did '
                 'not significantly reduce risk of PCR‑confirmed or suspected '
                 'SARS‑CoV‑2 infection in HCWs. HCQ was associated with a '
                 'statistically significant increase in adverse events.” '
                 'Numerical results: OR for PCR‑confirmed infection 0.92 (95% '
                 'credible interval 0.58–1.37); adverse events OR 1.35 (95% CI '
                 '1.03–1.73). (Extracted from the provided meta‑analysis '
                 'summary.)\n'
                 '- Guidance summary language (2023–2025 guidance context '
                 'excerpt in the evidence): WHO/other guidance pages '
                 'summarized CQ/HCQ status as: “Based on the arm of the '
                 'RECOVERY trial showing no clinical benefit, and other '
                 'clinical data with cardiotoxicity concerns” (phrase '
                 'appearing in guidance‑context extract). This ties the later '
                 'official framing to trial results showing no benefit plus '
                 'safety concerns.\n'
                 '- Retracted/contested analyses in 2024: one meta‑analysis '
                 '(Pradelle et al., Jan 2024) claimed high numbers of '
                 'HCQ‑related deaths, but the article was later retracted for '
                 '“lack of sufficiently reliable data” and “questionable '
                 'assumptions.” Critique of that work stressed misapplication '
                 'of effect sizes (borrowing ORs from high‑dose RCTs and '
                 'applying them across doses) and lack of dose‑subgroup '
                 'sensitivity analyses. Reanalysis indicated increased '
                 'mortality signal only in higher‑dose regimens; lower‑dose '
                 'regimens showed no clear evidence of increased mortality. '
                 '(Extracted from provided evidence about the Pradelle '
                 'retraction and critique.)\n'
                 '\n'
                 '4) Examples showing the claim is still repeated (2024–2025 '
                 'instances from the evidence; exact language reported)\n'
                 '- Recent article summary (date unspecified in evidence but '
                 'included among 2024–2025 items): “On March 28, the FDA '
                 'issued an Emergency Use Authorization (EUA) for '
                 'hydroxychloroquine to be used in hospitals to treat novel '
                 'coronavirus (COVID‑19) patients.… Preliminary international '
                 'research suggested hydroxychloroquine might speed recovery '
                 'in severely ill COVID‑19 patients, but a study published in '
                 'the New England Journal of Medicine showed it did not. The '
                 'FDA issued a caution against using hydroxychloroquine or '
                 'chloroquine to treat COVID‑19 outside a hospital setting or '
                 'a clinical trial because of potential side effects, '
                 'including heart arrhythmia.” (This passage shows repetition '
                 'of the original EUA narrative alongside the later '
                 'qualification.)\n'
                 '- Media/podcasts/activist circulation (historical '
                 'persistence noted in the evidence): the America’s Frontline '
                 'Doctors press conference (July 28, 2020) promoted HCQ as a '
                 'cure; within two weeks “at least 42 podcast episodes shared '
                 'claims about hydroxychloroquine’s efficacy.” The evidence '
                 'also states podcast conversations “skyrocketed” in summer '
                 '2020 and “remained a constant feature throughout the study '
                 'period.” (These are the indicators of early widespread '
                 'repetition and ongoing circulation.)\n'
                 '- Other recent news summaries (2024–2025): contemporary '
                 'summaries still recount the original EUA and note the early '
                 'hope and later FDA caution/revocation, sometimes phrased as '
                 '“the FDA initially listed hydroxychloroquine as a potential '
                 'treatment and prophylaxis… By June 2020 the FDA had revoked '
                 'hydroxychloroquine’s emergency use authorization (EUA).” '
                 '(Evidence cites multiple contemporary articles reiterating '
                 'the original claim and its later revocation.)\n'
                 '\n'
                 '5) How the language shifted over time — summary of the '
                 'reframing trajectory (based on the provided texts)\n'
                 '- Early wording (Mar–Apr 2020): authorization language and '
                 'reporting emphasized potential efficacy/availability — e.g., '
                 'EUA language permitting distribution “to be used… when a '
                 'clinical trial is not available or feasible,” and early '
                 'media descriptions presenting HCQ as “a potential treatment” '
                 'or as something that “might speed recovery.”\n'
                 '- Regulatory reversal (June 2020): FDA explicitly stated the '
                 'scientific criteria for EUA issuance were no longer met and '
                 'used strong qualifying language: HCQ/CQ “are unlikely to be '
                 'effective in treating COVID‑19 for the authorized uses,” and '
                 '“the known and potential benefits no longer outweigh the '
                 'known and potential risks.”\n'
                 '- Research/clinical framing (2023–2025): peer‑reviewed '
                 'syntheses and trial reports shifted the emphasis from '
                 'potential benefit to demonstrated lack of benefit and '
                 'documented harms: “did not demonstrate therapeutic benefit,” '
                 '“no clinical benefit (RECOVERY),” “did not significantly '
                 'reduce risk” (PrEP meta‑analysis), and repeated statements '
                 'of cardiotoxicity (QTc prolongation) and increased adverse '
                 'events. Guidance language condensed this to “no clinical '
                 'benefit, and cardiotoxicity concerns.”\n'
                 '- Contemporary public/media repetition: many modern accounts '
                 'still recount the initial EUA and early hopeful framing '
                 '(often in historical retelling) but now typically add the '
                 'revocation and trial findings. However, some public '
                 'discourse and some analyses (including later disputed or '
                 'retracted ones) reassert stronger harms or causal death '
                 'counts; those contested claims have sometimes been retracted '
                 'or heavily critiqued.\n'
                 '\n'
                 '6) Why the earlier framing persists — mechanisms documented '
                 'in the supplied evidence (no speculation beyond cited '
                 'mechanisms)\n'
                 'The supplied literature on misinformation dynamics and media '
                 'framing identifies multiple empirically supported mechanisms '
                 'that plausibly explain why early HCQ efficacy claims '
                 'continued to circulate after they were weakened by later '
                 'evidence. The evidence includes empirical summaries and '
                 'syntheses (2018–2025 findings) that I use here as documented '
                 'mechanisms:\n'
                 '\n'
                 '- Speed and novelty advantage of false or sensational '
                 'claims: empirical work summarized in the evidence shows '
                 'false news and novel/emotional stories “spread significantly '
                 'farther, faster, deeper, and more broadly” than true news. '
                 'Early claims that HCQ might work had novelty and emotional '
                 'resonance (hope, fear) that aided rapid spread before later '
                 'corrections could catch up.\n'
                 '- Early seeding and amplification by coordinated actors: the '
                 'evidence documents that automated accounts and coordinated '
                 'amplification can seed narratives early to create viral '
                 'momentum. The America’s Frontline Doctors conference and '
                 'immediate podcast amplification (42+ episodes within two '
                 'weeks; podcast conversations “skyrocketed”) illustrate early '
                 'seeding and rapid spread in HCQ’s case.\n'
                 '- Repetition/familiarity effects: repeated exposure '
                 'increases perceived truthfulness (“familiarity effect”). '
                 'High‑volume early coverage and sustained podcast/media '
                 'conversation create repeated exposure that makes the early '
                 'claim more persistent in public memory.\n'
                 '- Algorithmic amplification and editorial incentives: recent '
                 'reviews in the evidence show recommender systems and '
                 'engagement‑driven metrics privilege novelty and emotion; '
                 'these platform logics can sustain and re‑present early '
                 'frames to new audiences, reinforcing persistence even after '
                 'scientific reversal.\n'
                 '- Supply‑side science communication failures: the evidence '
                 'cites early publication of low‑quality or biased research '
                 'and limited public access to high‑quality findings as '
                 'seeding misinformation. Rapid, preliminary studies and '
                 'preprints in early 2020 likely contributed to the initial '
                 'authoritative sounding claims that HCQ “might” help.\n'
                 '- Cognitive and demographic factors: findings cited show '
                 'many people do not verify accuracy before sharing and older '
                 'demographics share fake news more often; these behavioral '
                 'patterns can sustain early claims in social networks.\n'
                 '- Institutional/political dynamics and elite promotion: the '
                 'evidence documents activist and elite promotion of HCQ '
                 '(e.g., America’s Frontline Doctors) and suggests that '
                 'influential endorsements can keep an initial frame alive '
                 'despite later scientific correction. The evidence also '
                 'documents that contested analyses (e.g., the retracted '
                 'Pradelle article) can briefly reintroduce strong claims into '
                 'circulation even if later withdrawn.\n'
                 '\n'
                 'The combined evidence supports a multi‑factor explanation '
                 '(speed of early spread + amplification + repetition + '
                 'algorithmic and editorial incentives + political/elite '
                 'promotion + limits in early science communication) for why '
                 'early HCQ efficacy claims continue to recur in media and '
                 'public discussion even after robust trial evidence and '
                 'regulatory revocation.\n'
                 '\n'
                 '7) Limitations, uncertainties, and missing data (explicit)\n'
                 '- Quantitative measures of current persistence are limited '
                 'in the provided evidence. While the evidence documents '
                 'podcast spikes (e.g., “at least 42 podcast episodes” in a '
                 'two‑week window in 2020 and that podcast coverage “remained '
                 'a constant feature”), it does not provide up‑to‑date counts '
                 'or engagement metrics (e.g., exact social‑media shares, '
                 'altmetric scores, or audience reach in 2024–2025) that would '
                 'quantify how commonly the early efficacy claim is repeated '
                 'today.\n'
                 '- Causal attribution is limited: the supplied mechanisms '
                 '(algorithms, bots, familiarity) are documented generally and '
                 'in other contexts; the evidence does not provide direct, '
                 'case‑level causal analyses tying any single mechanism to '
                 'persistence of HCQ claims in every instance. The mechanisms '
                 'are plausible and empirically supported in broader work '
                 'cited in the evidence, but the evidence does not show a '
                 'one‑to‑one causal chain for every repeating instance of the '
                 'HCQ claim.\n'
                 '- Some contested later claims are themselves disputed or '
                 'retracted (e.g., the Jan 2024 Pradelle paper claiming large '
                 'HCQ‑related death counts was retracted for “lack of '
                 'sufficiently reliable data”). This shows that not all later '
                 'claims that strengthen the “harm” narrative are reliable; '
                 'the evidence includes the retraction and the methodological '
                 'critiques that explain why that later claim was unreliable.\n'
                 '- Missing original source texts/URLs in the provided '
                 'material: while the evidence contains precise summaries and '
                 'quoted phrasings from FDA notices, systematic reviews, '
                 'meta‑analyses, and media items, full bibliographic citations '
                 '(DOIs/URLs) are not always given in the material I was '
                 'provided; where the evidence supplied exact phrasing or '
                 'clear metadata I used it directly, but I cannot provide '
                 'external retrieval links beyond what was included.\n'
                 '- Scope limitation: the evidence focuses on hospitalized '
                 'patients, HCW pre‑exposure prophylaxis trials, and safety '
                 '(QTc); it does not present a comprehensive dataset of every '
                 'HCQ trial or every public statement worldwide between '
                 '2020–2025. The conclusions are based on the provided samples '
                 '(regulatory actions, major RCT results summarized, '
                 'systematic reviews, and media/persistence analyses in the '
                 'provided corpus).\n'
                 '\n'
                 '8) Short, cautious conclusions grounded in the supplied '
                 'evidence\n'
                 '- The major early claim (2020–2022) that hydroxychloroquine '
                 'was an effective treatment for COVID‑19 was institutionally '
                 'enabled (EUA issued March 28, 2020) and widely repeated in '
                 'media and by advocacy groups. By June 15, 2020 the FDA '
                 'revoked the EUA, stating HCQ/CQ were “unlikely to be '
                 'effective” for the authorized uses and that harms outweighed '
                 'benefits. Subsequent randomized trials, meta‑analyses, and '
                 'guidance through 2023–2025 consistently found no '
                 'demonstrated therapeutic benefit in hospitalized patients or '
                 'for prophylaxis and documented cardiotoxicity (QTc '
                 'prolongation) and increased adverse events; official '
                 'guidance therefore reframed HCQ as not beneficial and as '
                 'carrying safety risks. Nonetheless, the initial efficacy '
                 'framing continues to appear in media summaries and public '
                 'discourse, supported by documented dynamics (rapid early '
                 'spread, amplification, repetition/familiarity, algorithmic '
                 'incentives, elite advocacy) described in the provided '
                 'evidence.  \n'
                 '- Remaining uncertainty: the evidence here documents '
                 'mechanisms that sustain early frames and provides multiple '
                 'examples of continued repetition, but it does not quantify '
                 'the present prevalence of the repeated claim or definitively '
                 'assign causal weight to any single mechanism in individual '
                 'repeated instances.\n'
                 '\n'
                 'If you want, I can:\n'
                 '- Extract and tabulate the exact quoted sentences and dates '
                 'from each of the main primary sources included in the '
                 'evidence (FDA EUA text, FDA revocation notice, key '
                 'systematic review summary sentences, PrEP meta‑analysis '
                 'numerical results, RECOVERY/WHO guidance wording), or\n'
                 '- Draft a short timeline graphic (text form) showing the '
                 'claim’s evolution (EUA → revocation → RCT/meta‑analysis '
                 'findings → contemporary media repeats and retractions) using '
                 'only the provided evidence.',
 'max_replans': 3,
 'plan': [{'expanded_goal': 'Identify one major, widely repeated claim made in '
                            '2020–2022 that is plausibly subject to later '
                            'weakening or reframing; produce a short '
                            'description of the claim and at least 3 '
                            'contemporaneous citations (news, govt, '
                            'peer-reviewed) and at least two indicators of '
                            'widespread repetition (e.g., citation counts, '
                            'major outlets repeating it, social media virality '
                            'metrics).',
           'goal': 'Identify one major, widely repeated claim made in '
                   '2020–2022 that is plausibly subject to later weakening or '
                   'reframing; produce a short description of the claim and at '
                   'least 3 contemporaneous citations (news, govt, '
                   'peer-reviewed) and at least two indicators of widespread '
                   'repetition (e.g., citation counts, major outlets repeating '
                   'it, social media virality metrics).',
           'id': 's1',
           'method': 'search',
           'produces_entities': ['candidate_claims_2020_2022_with_citations_and_repetition_indicators'],
           'requires_entities': [],
           'risk': 'low'},
          {'expanded_goal': 'For the selected claim from 2020–2022 (top '
                            'candidate in '
                            'candidate_claims_2020_2022_with_citations_and_repetition_indicators), '
                            'find primary sources from 2020–2022 that state '
                            'the claim and extract the exact '
                            'language/quotations and bibliographic metadata '
                            '(author, outlet, date, URL/DOI).\n'
                            '\n'
                            'Use the following context when executing this '
                            'step:\n'
                            '\n'
                            'Context for entity type '
                            'candidate_claims_2020_2022_with_citations_and_repetition_indicators:\n'
                            '1. No content on this page relates to an FDA '
                            'emergency use authorization for '
                            'hydroxychloroquine for COVID-19 (2020).\n'
                            '2. The page is a general USA.gov homepage with '
                            'links to government topics and services but '
                            'contains no EUA statement or related details.\n',
           'goal': 'For the selected claim from 2020–2022 (top candidate in '
                   'candidate_claims_2020_2022_with_citations_and_repetition_indicators), '
                   'find primary sources from 2020–2022 that state the claim '
                   'and extract the exact language/quotations and '
                   'bibliographic metadata (author, outlet, date, URL/DOI).',
           'id': 's2',
           'method': 'search',
           'produces_entities': ['original_claim_texts_and_sources_2020_2022'],
           'requires_entities': ['candidate_claims_2020_2022_with_citations_and_repetition_indicators'],
           'risk': 'low'},
          {'expanded_goal': 'Find peer-reviewed studies, official reports, or '
                            'major investigative articles from 2023–2025 that '
                            'present evidence which partially weakens or '
                            'reframes the selected 2020–2022 claim; for each '
                            'source extract the key findings, publication '
                            'metadata, and exact phrasing that reframes or '
                            'qualifies the original claim.\n'
                            '\n'
                            'Use the following context when executing this '
                            'step:\n'
                            '\n'
                            'Context for entity type '
                            'original_claim_texts_and_sources_2020_2022:\n'
                            '1. Date: March 28, 2020 — FDA issued an Emergency '
                            'Use Authorization (EUA).\n'
                            '2. Products covered: hydroxychloroquine sulfate '
                            'and chloroquine phosphate donated to the '
                            'Strategic National Stockpile (SNS).\n'
                            '3. Authorized use: to be distributed from the SNS '
                            'to states and used for certain hospitalized '
                            'patients with COVID-19 — specifically for '
                            'adolescent and adult patients hospitalized with '
                            'COVID-19, as appropriate, when a clinical trial '
                            'is not available or feasible.\n'
                            '4. EUA requirements: fact sheets providing '
                            'important information about using chloroquine '
                            'phosphate and hydroxychloroquine sulfate in '
                            'treating COVID-19 must be made available to '
                            'health care providers and patients, including the '
                            'known risks and drug interactions.\n'
                            '5. Distribution logistics: the SNS, managed by '
                            'the Assistant Secretary for Preparedness and '
                            'Response (ASPR), will work with the Federal '
                            'Emergency Management Agency (FEMA) to ship '
                            'donated doses to states.\n'
                            '6. This communication informs licensed '
                            'prescribers and dispensers of a recent FDA '
                            'guidance authorizing emergency use of chloroquine '
                            'phosphate and hydroxychloroquine sulfate.\n'
                            '7. The authorization details are described in the '
                            'Scope of Authorization (Section II) of the FDA '
                            'letter referenced by the communication; the '
                            'emergency use is for the treatment of COVID-19.\n'
                            '8. LARA (Michigan Department of Licensing and '
                            'Regulatory Affairs) acknowledges the role of '
                            'prescribers and dispensers and urges responsible '
                            'prescribing and dispensing practices.\n'
                            '9. Signed by: Debra Gagliardi, Director, Bureau '
                            'of Professional Licensing.\n'
                            '10. Date: 06/15/2020 — FDA revokes the emergency '
                            'use authorization (EUA) for chloroquine phosphate '
                            'and hydroxychloroquine sulfate.\n',
           'goal': 'Find peer-reviewed studies, official reports, or major '
                   'investigative articles from 2023–2025 that present '
                   'evidence which partially weakens or reframes the selected '
                   '2020–2022 claim; for each source extract the key findings, '
                   'publication metadata, and exact phrasing that reframes or '
                   'qualifies the original claim.',
           'id': 's3',
           'method': 'search',
           'produces_entities': ['later_evidence_reports_2023_2025_with_key_findings_and_quotes'],
           'requires_entities': ['original_claim_texts_and_sources_2020_2022'],
           'risk': 'medium'},
          {'expanded_goal': 'Collect examples from 2024–2025 where the '
                            'original 2020–2022 claim is still being repeated '
                            '(news articles, opinion pieces, public speeches, '
                            'organizational statements, or high-engagement '
                            'social media posts); extract the exact language '
                            'used and publication metadata for each example.\n'
                            '\n'
                            'Use the following context when executing this '
                            'step:\n'
                            '\n'
                            'Context for entity type '
                            'original_claim_texts_and_sources_2020_2022:\n'
                            '1. Date: March 28, 2020 — FDA issued an Emergency '
                            'Use Authorization (EUA).\n'
                            '2. Products covered: hydroxychloroquine sulfate '
                            'and chloroquine phosphate donated to the '
                            'Strategic National Stockpile (SNS).\n'
                            '3. Authorized use: to be distributed from the SNS '
                            'to states and used for certain hospitalized '
                            'patients with COVID-19 — specifically for '
                            'adolescent and adult patients hospitalized with '
                            'COVID-19, as appropriate, when a clinical trial '
                            'is not available or feasible.\n'
                            '4. EUA requirements: fact sheets providing '
                            'important information about using chloroquine '
                            'phosphate and hydroxychloroquine sulfate in '
                            'treating COVID-19 must be made available to '
                            'health care providers and patients, including the '
                            'known risks and drug interactions.\n'
                            '5. Distribution logistics: the SNS, managed by '
                            'the Assistant Secretary for Preparedness and '
                            'Response (ASPR), will work with the Federal '
                            'Emergency Management Agency (FEMA) to ship '
                            'donated doses to states.\n'
                            '6. This communication informs licensed '
                            'prescribers and dispensers of a recent FDA '
                            'guidance authorizing emergency use of chloroquine '
                            'phosphate and hydroxychloroquine sulfate.\n'
                            '7. The authorization details are described in the '
                            'Scope of Authorization (Section II) of the FDA '
                            'letter referenced by the communication; the '
                            'emergency use is for the treatment of COVID-19.\n'
                            '8. LARA (Michigan Department of Licensing and '
                            'Regulatory Affairs) acknowledges the role of '
                            'prescribers and dispensers and urges responsible '
                            'prescribing and dispensing practices.\n'
                            '9. Signed by: Debra Gagliardi, Director, Bureau '
                            'of Professional Licensing.\n'
                            '10. Date: 06/15/2020 — FDA revokes the emergency '
                            'use authorization (EUA) for chloroquine phosphate '
                            'and hydroxychloroquine sulfate.\n',
           'goal': 'Collect examples from 2024–2025 where the original '
                   '2020–2022 claim is still being repeated (news articles, '
                   'opinion pieces, public speeches, organizational '
                   'statements, or high-engagement social media posts); '
                   'extract the exact language used and publication metadata '
                   'for each example.',
           'id': 's4',
           'method': 'search',
           'produces_entities': ['present_day_repetition_examples_2024_2025_with_quotes_and_sources'],
           'requires_entities': ['original_claim_texts_and_sources_2020_2022'],
           'risk': 'low'},
          {'expanded_goal': 'Locate authoritative analyses (media studies, '
                            'policy analyses, cognitive science literature, '
                            'post-mortems, or think-tank reports, 2021–2025) '
                            'that discuss why initial framings persist despite '
                            'later qualification (e.g., media inertia, '
                            'incentives, cognitive bias, policy lock-in); '
                            'extract the main explanatory points with '
                            'citations.\n'
                            '\n'
                            'Use the following context when executing this '
                            'step:\n'
                            '\n'
                            'Context for entity type '
                            'later_evidence_reports_2023_2025_with_key_findings_and_quotes:\n'
                            '1. Eveleens Maarse BC et al. — Result: No '
                            'significant correlation between HCQ and RR-, '
                            'QRS-, or QTcF-intervals (P > 0.05). Conclusion: '
                            '"At plasma concentrations up to 200 ng/mL, HCQ '
                            'had no effect on ventricular repolarization '
                            'including QTcF and T‑wave shape."\n'
                            '2. Chorin E. et al. — Result: Severe new QTc '
                            'prolongation to ≥500 ms in 23% of cases. '
                            'Conclusion: "HCQ markedly lengthens QTc in '
                            'COVID‑19 patients."\n'
                            '3. Tang W. et al. — Result: QTc prolongation and '
                            'cardiac arrhythmia reported; no significant '
                            'difference in viral negative conversion versus '
                            'standard care. (Regimen reported: HCQ 1,200 mg OD '
                            'for 3 days then 800 mg OD for 2–3 weeks.)\n'
                            '4. Borba MGS. et al. (CQ trial) — Result: '
                            'Ventricular arrhythmia or QTc > 500 ms reported '
                            'at 28 days; higher-dose group had increased '
                            'occurrence of QTc > 500 ms. Conclusion: '
                            '"High‑dose CQ not recommended for critically ill '
                            'patients."\n'
                            '5. van den Broek et al. — Result: Mean QTc '
                            'prolongation 35 ms (95% CI 28–43 ms). Conclusion: '
                            '"Chloroquine significantly prolongs QTc '
                            'interval."\n'
                            '6. Bessière F. et al. — Result: 93% of patients '
                            'displayed an increase in QTc. Conclusion: "QTc '
                            'intervals increased in >90% of patients."\n'
                            '7. Ramireddy et al. — Result: Baseline mean QTc '
                            '448 ± 29 ms increased to 459 ± 36 ms (P = 0.005); '
                            'critical QTc prolongation present in 12% of '
                            'patients overall.\n'
                            '8. Cipriani et al. — Result: QTc interval longer '
                            'after treatment (p = 0.02). Conclusion: '
                            '"Azithromycin + HCQ prolong QTc, especially with '
                            'high transaminase levels."\n'
                            '9. Bun SS et al. — Result: Average automated QTc '
                            'prolonged after 48 hr. Conclusion: "Combination '
                            'therapy with HCQ/AZT may be used in inpatients '
                            'with lower respiratory tract infection but QTc '
                            'increases observed."\n'
                            '10. Aggregate finding — Reported range of '
                            'significant QTc prolongation across included '
                            'studies: 12% to 93% of patients.\n'
                            '\n'
                            '\n'
                            'Context for entity type '
                            'present_day_repetition_examples_2024_2025_with_quotes_and_sources:\n',
           'goal': 'Locate authoritative analyses (media studies, policy '
                   'analyses, cognitive science literature, post-mortems, or '
                   'think-tank reports, 2021–2025) that discuss why initial '
                   'framings persist despite later qualification (e.g., media '
                   'inertia, incentives, cognitive bias, policy lock-in); '
                   'extract the main explanatory points with citations.',
           'id': 's5',
           'method': 'search',
           'produces_entities': ['persistence_explanations_and_sources_2021_2025'],
           'requires_entities': ['later_evidence_reports_2023_2025_with_key_findings_and_quotes',
                                 'present_day_repetition_examples_2024_2025_with_quotes_and_sources'],
           'risk': 'medium'}],
 'replan_count': 0,
 'replan_request': None,
 'research_brief': None,
 'supervisor_decision': 'TERMINATE',
 'termination_reason': 'Plan completed',
 'user_query': 'Find a major claim from 2020–2022 that is still repeated today '
               'but has been partially weakened or reframed by later evidence. '
               'Show how the language changed over time and why the earlier '
               'framing persists.'}